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Preamble
Our mission was to develop evidence-based guidelines for the prevention and treatment of 
perioperative atrial fibrillation and flutter (POAF) for thoracic surgical procedures. Sixteen 
experts were invited by the AATS leadership: 7 cardiologists and EP specialists, 3 
intensivists/anesthesiologists, 1 clinical pharmacist, joined by 5 thoracic and cardiac 
surgeons who represented AATS (see E1: list of members and E2: conflict of interest 
declaration online).
Methods of review
Members were tasked with making recommendations based upon a review of the literature, 
with grading the quality of the evidence supporting the recommendations, and with 
assessing the risk benefit profile for each recommendation (table 1). The level of evidence 
was graded by the task force panel according to standards published by the Institute of 
Medicine (table 1). For the development of the guidelines we followed the recommendations 
of The Institute of Medicine (IOM) 2011 “Clinical Practice Guidelines We Can Trust: 
Standards for Developing Trustworthy Clinical Practice Guidelines; www.iom.edu/
cpgstandards” [1]. In order to meet these standards most societies (American Heart 
Association and AATS included) initiated the revision [2], [3] of existing guidelines [4].
For our task force subgroups were formed and tasked with preparing a summary of the 
available literature for each subtopic. Literature searches were conducted using Pubmed®, 
focused on articles published since 2000 except in rare circumstances. Both our summaries 
and original articles were made available to each task force member via a shared electronic 
folder. The subgroup summaries as well as original literature were presented and discussed 
at nine scheduled teleconferences. The conferences were recorded. Articles were selected for 
inclusion based on consensus opinion by task force members. Writing groups were formed 
to develop the draft guidelines for each subtopic, with 3–7 members and a leader for each 
group. Group recommendations were submitted prior to, and, subsequently presented for 
discussion and voting at, a one-day face-to-face conference.
Members were specifically asked to assess the applicability of the available evidence to 
thoracic surgery patients. All recommendations were subjected to a vote. Acceptance for the 
final document required >75% approval of each of the recommendations.
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A final draft was prepared by the chairman of the task force and made available in a written 
form to each member for final comments. Subsequently, the recommendations were posted 
for public comments for AATS members (via REDCap), and then peer reviewed by outside 
experts selected by AATS Council.
The following recommendations are based on the best available evidence from thoracic 
surgery. When thoracic surgery specific evidence was not available, we extrapolated from 
the cardiac surgical literature. In the absence of direct evidence, we present the best expert 
opinion based on cardiology/cardiac electrophysiology experience and best practices.
An executive summary was prepared for publication in a printed format, while this more 
extensive guideline was prepared for on-line publication with additional comments, data, 
and a comprehensive list of references.
AATS member survey
Our survey of the AATS members (results presented in E3 online) indicated the need for a 
guideline update and identified opportunities for improvement in the areas of prevention, 
standards for postoperative ECG monitoring and the use of novel oral anticoagulants.
Target audience and patient population
These guidelines are intended for all non-cardiac intra-thoracic surgeries and 
esophagectomies, as well as for patients whose risk factors and comorbidities place them at 
intermediate to high risk for POAF independent of the procedures. In assessing the patient’s 
risk for POAF it must be noted that the risks posed by the procedure and by patient factors/
comorbidities will likely be additive, if not synergistic. Therefore, these factors should be 
evaluated in combination during the preoperative assessment.
The target audience includes not only thoracic surgeons and anesthesiologists but all 
providers who participate in the care of thoracic surgical patients.
The following novel information is included in this 2014 document: (i) standardized 
definitions for AF and (ii) recommendations for: (a) ECG monitoring, (b) post-discharge 
management, (c) use of the new-class of novel oral anti-coagulants (NOAC); and (d) 
obtaining cardiology consultation. Additionally, flow diagrams summarize the strategies for 
acute and chronic management. Specific drug recommendations and dosing tables are also 
included.
Epidemiology of perioperative atrial fibrillation and flutter (POAF), its 
impact on outcomes, cost and morbidity
Atrial fibrillation, the most common sustained arrhythmia after pulmonary and esophageal 
surgery, is a major, potentially preventable, adverse outcome. POAF peaks on postoperative 
days 2–4, however, 90–98% of new onset POAF resolves within 4–6 weeks. Post-operative 
atrial fibrillation has multiple negative implications. In the acute setting, the tachyarrhythmia 
can lead to hemodynamic instability, necessitating prompt intervention. A sustained elevated 
Frendl et al. Page 3













heart rate can result in heart failure, a less common but clinically devastating situation, the 
incidence of which is not reported in the literature.
The incidence of POAF varies widely based on the intensity of surgical stress (table 2a; 
Refs:[5]–[17]) and patient characteristics (table 2b; Refs: [5], [6], [8], [10], [18]–[20]). Some 
of the risk factors for AF like HTN, obesity, and smoking, are modifiable, while others, like 
older age, Caucasian ancestry, and male sex are not.
Thromboembolic events such as stroke or acute limb ischemia are the most serious and 
feared consequences of atrial fibrillation. Studies have reported a wide range of the 
incidence of stroke related to POAF, though the risk appears to be increased by 50–200% 
for cardiac and thoracic surgical patients over the risk of general surgery [10], [21], [22].
Many studies show an increase in mortality in patients with POAF [6], [10], [15], [16], [23], 
[24] though some studies have not shown such an effect [13], [25]. Given that patients with 
other significant comorbidities or who are undergoing more complex operations are more 
likely to experience POAF, it is unclear to what extent the arrhythmia itself contributes to 
mortality. It is feasible that the contribution of POAF to mortality is more significant for 
those patients with fewer other comorbidities however this independent effect is more 
difficult to measure and has not been well reported in the literature.
POAF is associated with longer intensive care unit and hospital stays, increased morbidity 
(including strokes/new central neurological events; with incidence of 1.3–1.7 %; [2], [10], 
[26]–[29] and mortality (up to 5.6–7.5%; RR:1.7–3.4; [5], [26], [28]), as well as higher 
resource utilization [2], [6], [10], [26]–[30].
Multiple studies have consistently demonstrated an increase in length of hospital stay in 
patients who develop POAF, generally by a mean of 2 to 4 days [5], [6], [8], [10], [15], [16], 
[19], [23], [24]. An analysis of the STS database by Onatis et. al., demonstrated that in 
patients undergoing lobectomy or greater resection for lung cancer, the presence of POAF 
lengthened hospital stay by a median of 3 days [10]. The cost of hospitalization is likewise 
increased for patients who develop POAF, with an increase reported in the literature 
anywhere from 30–68% [5], [6], [23]. To some extent, this increase reflects comorbid 
conditions that occur along with POAF, but POAF itself is associated with an increase in 
cost. Vaporciyan et al. found that for patients who developed POAF without any other 
complications, the cost of care increased by over $6,000, representing a greater than 30% 
increase [5].
The possible mechanisms of POAF following thoracic surgery
The mechanisms that initiate and sustain atrial fibrillation (AF), including POAF, are 
complex and require both a vulnerable atrial substrate [31] and a trigger to initiate AF (table 
3). Today they remain incompletely understood. The role of triggers from the pulmonary 
veins and other atrial sites initiating AF [32] is well appreciated. However, it remains to be 
understood why they occur and what exact mechanisms are essential for their propagation. 
The identified risk factors for the development of sustained POAF are mostly identical to 
those known to make the atrium vulnerable to development of AF in the non-surgical 
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setting. They include several risk factors that are associated with atrial fibrosis, such as 
increasing age, atrial dilatation, myocardial ischemia, volume overload, and a history of 
heart failure [33]–[35]. They also include risk factors like elevated norepinephrine levels and 
increased vagal tone, both of which shorten atrial wavelength, the latter known to increase 
atrial vulnerability to AF [36]. Interestingly, both adrenergic and vagal stimulation can 
promote triggers that initiate AF [37]. In addition, surgical procedures are associated with 
local or systemic inflammation (like pericarditis), an important risk factor affecting the 
vulnerability of the atrial substrate to POAF [38]. The extent of pulmonary resection is 
another important risk factor for development of POAF [7]. The development of POAF is 
likely to involve some or all of these mechanisms.
We can gain some insight into the mechanism of POAF by examining what prophylactic 
therapies decrease the rate of POAF occurrence following thoracic surgery. Higher 
norepinephrine levels were found in patients on preoperative beta-blockers who had their 
beta-blocker therapy interrupted than in patients not receiving a beta-blockers at all. This 
was associated with a significantly higher incidence of POAF [34], [39].
Diltiazem therapy initiated in the early postoperative period has been found to significantly 
reduce the rate of POAF [27]. This is thought to be related to its effects of decreasing 
pulmonary vascular resistance. It is known that pulmonary hypertension and dilatation of the 
right side of the heart are associated with an increased incidence of POAF [33]. There is also 
the possibility that as a systemic vasodilator, diltiazem could reduce preload and left atrial 
pressures [33]. Of note, the data on use of verapamil have been inconsistent with regard to 
decreasing the incidence of POAF [40]. Finally, magnesium has been consistently shown to 
decrease the incidence of POAF after cardiac surgery, and the only prospective, randomized 
study in thoracic surgery patients also showed a significant decrease in the incidence of 
POAF [39]. The reason for its effectiveness is uncertain.
In the presence of a vulnerable substrate, additional electrophysiologic abnormalities 
(drivers) will sustain AF.
RECOMMENDATIONS AND REASONING
1. Recommend the use of the following definitions for the diagnosis of post-operative 
atrial fibrillation and flutter (POAF) (table 4)
Class I
1.1. Electro-physiologic definition/diagnosis: ECG recordings (one or more ECG leads) 
which demonstrate the presence of characteristic ECG features of AF lasting at least for 
30 seconds or for the duration of the ECG recording (if shorter than 30 seconds) [2], 
[29]. (LOE C)
1.2. Clinical definition/diagnosis: Clinically significant POAF is AF in the (intra- and) 
post-operative setting which requires treatment with rate or rhythm control agents, or 
requires anticoagulation, and/or extends the duration of hospitalization. (LOE C)
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We recommend that both electro-physiologically documented AF and clinically 
diagnosed AF be included in the clinical documentation and reported in the clinical 
trials/studies.
2. Physiologic (ECG) monitoring of patients at risk for POAF (table 5)
Recommendations for the ECG monitoring of the patients at risk for POAF are presented in 
table 5.
Class I
2.1. Patients should be monitored with continuous ECG telemetry postoperatively for 
48–72 hours (or less if their hospitalization is shorter) if:
2.1.1. They are undergoing procedures that pose intermediate (5–15% expected 
incidence of AF) or high (>15%) risk for the development of postoperative AF or 
have significant additional risk factors (CHA2DS2-VASc ≥ 2) for stroke. (LOE C)
2.1.2. They have a history of preexisting or periodic recurrent AF before their 
surgery. These patients should also receive ECG monitoring in the immediate pre-
operative period if procedures (epidural catheter, regional anesthesia blocks, etc.) are 
performed. (LOE C)
Class IIa
2.2. Not using routine ECG telemetry is reasonable for patients who undergo low risk 
(<5% expected incidence of AF) procedures, and have neither prior history of AF, nor 
significant risk for stroke (based on CHA2DS2-VASc score), and have no relevant co-
morbidities (such as heart failure or prior stroke). (LOE C)
Class I
2.2.1. If patients exhibit clinical signs of possible AF while not monitored with 
telemetry ECG recordings to diagnose POAF and ongoing telemetry to monitor the 
period of AF should be immediately implemented. (LOE C)
3. Rate control and anti-arrhythmic drugs, mechanism of action, side effects and 
limitations
A detailed description of the drugs used for the management of rate (table 6) or rhythm-
control (table 7, [41]) their mechanism of action, side effects, and limitations are discussed 
here. Dosing information is also presented in tables 6 and 7.
RECOMMENDATION
Class IIa
3.1. To optimize the efficacy and safety of amiodarone, it is reasonable to exercise 
caution when selecting its doses or intravenous vs. oral route, because cases of ARDS 
have been reported following pneumonectomy with cumulative intravenous doses 
above 2,150 mg [42]. (LOE C)
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3.2. Rate control agents – their mechanisms of action and side effects
3.2.1. β-blockers: β-blockers are Vaughan Williams class II anti arrhythmic agents that 
inhibit sympathetic nervous system activity and slow the rate of phase IV repolarization, 
thus slowing the discharge from the sinus node [43]. This antiadrenergic activity inhibits the 
renin angiotensin aldosterone system, inhibits apoptosis, and reduces hyperphosphorylation 
of calcium releasing channels [44]. Metoprolol and atenolol are relatively selective β-1 
receptor antagonists (primarily affecting cardiac tissue) and in moderate doses have less 
effect on the β-2 receptors in smooth muscle cells in the vasculature and bronchial tree. 
Propranolol and esmolol are nonselective, and carvedilol is nonselective and possesses α-
receptor blocking activity.
Intravenous administration of metoprolol, propranolol and esmolol reduces ventricular 
response in patients with atrial fibrillation (AF) within 5 minutes of administration [45], and 
both intravenous and oral regimens attain resting and exercise rate control, variably defined, 
in 68–75% of patients [28], [46]–[48]. Rate lowering efficacy varies with acuity and cardiac 
function and is enhanced with digoxin [46], [47].
The major adverse effects of β-blockers are bronchospasm in patients with asthma, 
particularly if the asthma is not well controlled; worsening of symptoms in patients with 
severe peripheral arterial disease; hypotension, and worsening of heart failure symptoms in 
patients with decompensated heart failure with reduced ejection fraction (HFrEF). 
Intravenous β-blockers should not be used in patients with suspected accessory conduction 
pathways [2], [3], [45]. Profound bradycardia can result from acute concomitant 
administration of β-blockers and diltiazem or verapamil.
3.2.2. Diltiazem: Diltiazem is a nondihydropyridine calcium channel antagonist and class IV 
Vaughan Williams agent. Diltiazem inhibits L-type calcium channels in vascular and 
conduction tissue, and especially in nodal tissue [49]. Additionally, diltiazem affects the 
transient outward and ultrarapid delayed rectifier potassium currents in atrial myocytes 
{Gao:2005ge}. Intravenous diltiazem administered as a bolus and continuous infusion can 
control ventricular response in 70–90% of patients with the recent onset of AF. The onset of 
action of diltiazem is 2–7 minutes [45], [50], [51].
Oral treatment with diltiazem in the Atrial Fibrillation Follow-Up Investigation of Rhythm 
Management (AFFIRM) trial was efficacious in controlling rest and exercise heart rate in 
approximately 60% of patients, and in 66% and 79% of patients, respectively, when 
combined with digoxin [46].
Diltiazem can worsen heart failure in patients with HFrEF, and can cause important 
gastrointestinal adverse effects including ileus. Diltiazem must be used cautiously, 
especially acutely, in patients concomitantly receiving β-blockers, and is contraindicated in 
patients with an accessory pathway [45].
3.2.3. Digoxin: Digoxin inhibits sodium potassium adenosine triphosphatase (ATPase), 
thereby increasing intracellular sodium concentration leading to increased intracellular 
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calcium concentrations. Additionally, digoxin administration is associated with an increase 
in baroreceptor sensitivity disproportionate to hemodynamic improvement, and imparts 
vagomimetic (parasympathetic) effects. The vagomimetic effects of digoxin occur at low 
serum concentrations and contribute to decreasing sinus and AV nodal conduction. At 
higher serum concentrations, the parasympathetic effects actually shorten the refractory 
period of non-nodal specialized conduction tissue [52].
The onset of action of digoxin following intravenous administration of 0.5–0.75 mg bolus 
doses is 30 minutes to 2 hours [53], [54]. With additional intravenous bolus doses of 0.25 
mg every 2–6 hours after the first dose, up to a total dose within 24 hours of 1.25–1.5mg, 
75% of patients with AF can achieve rate control at rest [50], [51]. Exercise rate control is 
achieved much less frequently, except when digoxin is administered concomitantly with a β-
blocker or calcium channel blocker [46].
Digoxin should not be administered to patients with suspected accessory pathways or 
obstructive hypertrophic cardiomyopathy. The potential for digoxin toxicity, including 
accelerated junctional rhythm, accelerated ventricular escape rhythms (sometimes heralded 
by regularization of the longest R-R intervals), nausea, and visual symptoms is increased in 
the presence of hypokalemia, hypomagnesemia, hypercalcemia and concomitant therapy 
with amiodarone, dronedarone or verapamil [2], [3], [45]. Propensity matched comparisons 
in the AFFIRM trial do not suggest an increase in mortality associated with chronic digoxin 
use [55].
3.2.4. Amiodarone: Amiodarone is a Vaughan Williams class III agent that inhibits inward 
potassium current, prolonging the action potential. However, amiodarone also has properties 
that could place it in the other three Vaughan Williams classes. It has antisympathetic and 
calcium blocking activity that lead to important effects on the sinoatrial (SA) and 
atrioventricular (AV) nodes, and the drug also has sodium channel inhibiting properties that 
increases the threshold for depolarization ([56] and Sanoski CA, Antiarrhythmic agents. pp:
61–88. In: [57])
Intravenous amiodarone, administered as a bolus and continuous infusion, has an effect on 
heart rate within 4 hours that is similar to intravenous diltiazem and intravenous digoxin, 
and improves ventricular rate in 74% of patients with AF by 24 hours [51]. Oral amiodarone 
can require days for effective rate control to occur. Chronic oral amiodarone therapy for rate 
control can have effects similar to those of digoxin [2], [3], [58].
Amiodarone is highly lipophilic, and intravenous administration may exert effects that are 
different from those following oral administration. Intravenous amiodarone can be 
associated with AV block, vasodilation and hypotension. Intravenous amiodarone should not 
be used in patients who have a suspected accessory pathway [2], [3]. Pulmonary toxicity 
associated with high dose intravenous amiodarone is discussed later (in section 3.5.1).
Chronic administration of oral amiodarone can be associated with pulmonary, hepatic, 
thyroid, neurologic, cutaneous, and ocular toxicities [45]. Amiodarone inhibits the 
metabolism of warfarin and inhibits elimination of the new oral anticoagulants. Amiodarone 
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administration can restore sinus rhythm so patients who receive it after 24–48 hours of AF 
require anticoagulation.
3.3. Antiarrhythmic medications (mechanisms of action, side effects)
3.3.1. Amiodarone (see section 3.2.4. above)
3.3.2. Flecainide: Flecainide is a Vaughan Williams class IC antiarrhythmic agent that is a 
potent inhibitor of fast sodium conduction [43]. Consequently, flecainide decreases the 
maximum upstroke velocity and amplitude of atrial, ventricular and Purkinje fiber action 
potentials [59]. Flecainide may also inhibit IKr current, and prolongs atrial and ventricular 
action potential duration. In patients without structural heart disease, oral flecainide is 
relatively well-tolerated; adverse effects include dizziness (15–20%) and visual 
abnormalities, including blurred vision and difficulty in focusing (up to 15%), which can 
usually occur during dose up-titration [60]. However, in patients with structural heart 
disease, flecainide is associated with more severe adverse effects. Flecainide is associated 
with ventricular proarrhythmia in this population; this proarrhythmia is not torsades de 
pointes (TdP), but rather monomorphic ventricular tachycardia. This proarrhythmia was the 
likely cause of death associated with flecainide (and encainide) in the Cardiac Arrhythmia 
Suppression Trial (CAST; [61]), in which patients with a history of myocardial infarction 
and symptomatic or asymptomatic ventricular ectopy [≥ 6 ventricular premature 
depolarizations (VPDs) per hour] were randomized to receive flecainide, another Vaughan 
Williams class IC agent encainide, or placebo for VPD suppression. Patients randomized to 
receive therapy with flecainide or encainide had an increased risk of total mortality and an 
increased risk of nonfatal cardiac arrest and death from arrhythmia. The risk of 
proarrhythmia associated with Vaughan Williams class IC antiarrhythmic agents seems to be 
highest in patients with ventricular conduction delays (QRS duration > 120 ms), structural 
heart disease, ventricular scar tissue, or left ventricular dysfunction [62]. Consequently, 
flecainide should be avoided in these patients.
In addition to the risk of proarrhythmia, flecainide has potent negative inotropic activity, and 
has been associated with worsening heart failure in patients with coronary artery disease or 
pre-existing heart failure (New York Heart Association class II–IV and/or left ventricular 
ejection fraction < 30%; [60]). Therefore, flecainide is contraindicated in patients with heart 
failure and reduced ejection fraction.
Intravenous flecainide is not available in the US, but is available in other countries. In 
addition to the potential for ventricular proarrhythmia in patients with structural heart 
disease and worsening of heart failure in patients with left ventricular dysfunction, 
intravenous flecainide may be associated with hypotension.
3.3.3. Magnesium: Intravenous magnesium is often referred to as a “physiologic” calcium 
channel blocker, owing to its antagonism of L- and T-type calcium channels [63]. 
Intravenous magnesium diminishes atrial automaticity [64]) and inhibits atrioventricular 
(AV) node conduction [65]. Intravenous magnesium is well-tolerated; sinus bradycardia or 
AV block have been reported with an incidence of approximately 3% [66]. Intravenous 
magnesium may also cause hypotension (approximate incidence 4%; [66]). Transient 
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adverse effects including flushing, tingling, and dizziness may occur in up to 17% of 
patients [66].
3.3.4. Dofetilide: Dofetilide is a Vaughan Williams class III antiarrhythmic agent that 
inhibits IKr current [67], and prolongs atrial and ventricular action potential duration [68]. 
While dofetilide has been shown to be effective for converting nonsurgical AF to sinus 
rhythm [69] and for maintenance of sinus rhythm in patients with nonoperative AF [70], it 
has not been studied specifically for prevention or management of AF following noncardiac 
thoracic surgery. As a result of its propensity to inhibit IKr and prolong ventricular 
repolarization, dofetilide may cause TdP, with an incidence of approximately 1% in patients 
with normal left ventricular function [68]. However, the incidence increases to 3.3% in 
patients with heart failure with reduced left ventricular ejection fraction [71]. To minimize 
the risk of TdP, dofetilide doses must be appropriately adjusted for kidney disease [2], [3].
3.3.5. Dronedarone: Dronedarone is a Vaughan Williams class III antiarrhythmic agent that 
was developed as a potentially safer congener of amiodarone. Dronedarone is similar to 
amiodarone with respect to the fact that it inhibits multiple ion currents, including fast Na+ 
current, IKr, acetylcholine-activated K+ current, and L-type calcium current [72]. 
Dronedarone is also a noncompetitive β-adrenergic inhibitor. Unlike amiodarone, however, 
which possesses two iodine atoms that compose 37% of its molecular weight, dronedarone’s 
structure does not include iodine atoms. In addition, the half-life of dronedarone (13–31 
hours) is much shorter than that of amiodarone (10–40 days; [72]). Dronedarone’s primary 
adverse effects include gastrointestinal distress (16%), dizziness (9%), and bradycardia (3%; 
[72]). Dronedarone was associated with an increased incidence of mortality in a randomized, 
double-blind, placebo-controlled study [73], and therefore is contraindicated in patients with 
New York Heart Association (NYHA) class III–IV heart failure, and in those patients with 
unstable NYHA class II heart failure.
Dronedarone has been shown to be effective for maintenance of sinus rhythm in patients 
with nonsurgical paroxysmal AF. Dronedarone is contraindicated in patients with permanent 
AF, due to increased mortality associated with dronedarone in that patient population [74]. 
The efficacy of dronedarone for maintenance of sinus rhythm in patients with nonsurgical 
AF has not been investigated.
3.3.6. Ibutilide: Ibutilide is a Vaughan Williams class III antiarrhythmic agent that exerts its 
antiarrhythmic activity via activation of slow inward sodium current [75] and inhibition of 
IKr [76]. Ibutilide is effective for conversion of atrial flutter and fibrillation to sinus rhythm 
[77]. Ibutilide is not available in an oral dosage form, and therefore is not used for 
maintenance of sinus rhythm. Ibutilide has been shown to be effective for conversion to 
sinus rhythm of AF occurring following coronary artery bypass graft surgery [78]. The 
efficacy of ibutilide for conversion to sinus rhythm of AF following noncardiac surgery has 
not been investigated.
The primary adverse effect associated with ibutilide is TdP, which occurs in 1–3% of 
patients. The incidence of TdP is 2–3-fold higher in patients with heart failure due to 
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reduced ejection fraction, which is a known risk factor for TdP. Ibutilide may also cause 
non-sustained monomorphic ventricular tachycardia in up to 8% of patients.
3.3.7. Procainamide: Procainamide is a Vaughan Williams class IA antiarrhythmic agent 
that exerts its antiarrhythmic effects through inhibition of fast sodium current as well as 
inhibition of IKr. In addition, a primary metabolite of procainamide, N-acetylprocainamide 
(NAPA), inhibits IKr current and contributes to the overall antiarrhythmic activity of 
procainamide. Procainamide is effective for conversion of nonoperative AF to sinus rhythm 
[79]. The efficacy of procainamide for conversion to sinus rhythm of AF following 
noncardiac thoracic surgery has not been investigated. Procainamide is no longer available 
in an oral dosage form, and therefore is no longer indicated for maintenance of sinus rhythm 
in patients with nonsurgical AF.
The primary adverse effects associated with intravenous procainamide are hypotension, QT 
interval prolongation and TdP, and lengthening of the QRS complex.
3.3.8. Propafenone: Propafenone is a Vaughan Williams class IC antiarrhythmic agent that 
is a potent inhibitor of sodium conductance [80]. Propafenone may also inhibit the transient 
outward potassium current (Ito) and the ultra-rapid delayed rectifier potassium (Ikur) current 
in atrial myocytes [81]. Propafenone is effective for maintenance of sinus rhythm in patients 
with nonoperative AF [82]. In addition, single-oral dose propafenone is effective for 
conversion of nonsurgical AF to sinus rhythm [83]. The efficacy of propafenone for 
prophylaxis or management of AF following noncardiac thoracic surgery has not been 
investigated.
Oral propafenone is well tolerated overall. Adverse effects include dizziness and blurred 
vision. However, propafenone possesses negative inotropic activity, and is contraindicated 
in patients with heart failure due to reduced ejection fraction [2], [3]. In addition, 
propafenone is contraindicated in patients with coronary artery disease or a history of 
myocardial infarction. Although propafenone was not studied in the CAST trial, the effects 
of flecainide and encainide in that study are believe to be due to potent sodium channel 
inhibition, and contraindications in patients with structural heart disease have been applied 
to propafenone.
3.3.9. Sotalol: Sotalol is an adrenergic β-receptor blocking agent [84] that also prolongs 
atrial and ventricular action potential duration via inhibition of IKr [85]. Sotalol is effective 
for reducing the incidence of recurrent AF in patients with paroxysmal AF [86] and after 
conversion to sinus rhythm [87]. Sotalol has not been shown to be effective for conversion 
of AF to sinus rhythm. Sotalol has been used to reduce the risk of AF following CABG 
surgery [88]. However, the efficacy of sotalol for prophylaxis of AF after noncardiac 
thoracic surgery has not been investigated.
3.3.10. Quinidine: Quinidine is a Vaughan Williams class IA antiarrhythmic agent that 
inhibits sodium conduction [89] as well as conductance of a variety of potassium currents, 
including IKr, IKI and Ito [90]. The use of oral quinidine for management of AF has largely 
been discontinued, due to evidence that quinidine may increase mortality [2], [3], [91]. 
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Quinidine may prolong the QT interval and cause TdP. The efficacy of quinidine for 
prevention or management of AF after noncardiac thoracic surgery has not been evaluated.
3.4. Serum drug concentration monitoring
3.4.1. Digoxin – serum drug concentration monitoring maybe warranted only if toxicity is 
of concern: Digoxin has a narrow therapeutic index, meaning that serum concentrations 
required for efficacy are similar to those that may cause toxicity. When used for heart 
failure, the desired therapeutic range is 0.5–0.9 ng/mL [92]. The optimal therapeutic range 
for digoxin for management of AF has not been established. The incidence of adverse 
effects associated with digoxin increases with serum concentrations > 2 ng/mL [93].
During management of AF following noncardiac thoracic surgery, monitoring of serum 
digoxin concentrations for assessment of efficacy is not necessary, as a strong relationship 
between rate control efficacy and serum digoxin concentration has not been established. 
Determination of serum digoxin concentration may be warranted if patients exhibit 
symptoms of digoxin toxicity, including nausea, vomiting, anorexia, or ventricular 
arrhythmias. If a serum concentration is thought to be necessary, the blood sample should be 
obtained at least 12 hours, and preferably 24 hours following the previous digoxin dose, as a 
result of the prolonged tissue distribution phase (Schentag JJ et al., Digoxin. pp 410–439 In: 
[94]); if the blood sample is obtained < 12 hours following the dose, the serum concentration 
may be falsely elevated, due to incomplete distribution of digoxin from serum to tissue.
To reduce the risk of digoxin toxicity in patients receiving the drug for AF after noncardiac 
thoracic surgery, serum digoxin concentration monitoring may be warranted if digoxin 
therapy must be continued for longer than one week, for those patients who remain in AF 
following hospital discharge. For patient with normal kidney function, the half-life of 
digoxin is approximately 36 hours; therefore, steady state serum concentrations require 
approximately one week. Routine determination of a steady state serum digoxin 
concentration after one week of therapy is not required in all patients. However, 
determination of a serum digoxin concentration after one week of therapy may be warranted 
in patients with chronic kidney disease or acute kidney injury, or in patients who are treated 
concomitantly with a drug that inhibits digoxin elimination, such as amiodarone, 
dronedarone, propafenone, quinidine, and verapamil (Schentag JJ et al., Digoxin. pp 410–
439 In: [94]).
3.4.2. Procainamide – serum drug concentration monitoring is not warranted: The 
suggested therapeutic range for procainamide efficacy is 4–10 mg/L (Bauman JL et al., 
Clinical pharmacokinetics of oral antiarrhythmic drugs. pp 440–462 In: [94]). However, this 
therapeutic range was determined using suppression of ventricular premature depolarizations 
and prevention of episodes of ventricular tachycardia. Serum procainamide concentrations 
have not been correlated with efficacy in AF, and therefore, desired serum procainamide 
concentrations for efficacy in AF are unknown. Serum concentration monitoring for 
intravenous procainamide for management of AF after noncardiac thoracic surgery is not 
warranted. The risk of adverse effects associated with intravenous procainamide can be 
minimized by terminating the loading dose of 20–50 mg/min continuous infusion if 
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hypotension occurs, QRS duration is prolonged by 50%, or a cumulative intravenous dose of 
17 mg/kg has been administered [41].
3.4.3. Amiodarone – serum drug concentration monitoring is not warranted: Serum 
amiodarone concentration monitoring has been performed during therapy for ventricular 
arrhythmias. However, a relationship between serum amiodarone concentrations and 
efficacy for prevention or management of AF has not been established. Similarly, a 
relationship between serum amiodarone concentrations and the majority of amiodarone’s 
adverse effects, particularly those that occur during short-term therapy, has not been 
established. Therefore, monitoring of serum amiodarone concentrations during prophylaxis 
or management of AF following noncardiac thoracic surgery is not warranted. However, to 
minimize the risk of pulmonary toxicity it is recommended to keep total cumulative 
intravenous amiodarone doses below 2,150mg.
3.4.4. Flecainide – serum drug concentration monitoring is not warranted: The 
therapeutic range for serum flecainide concentrations is often cited as 0.3–2.5 mg/L 
(Bauman JL et al., Clinical pharmacokinetics of oral antiarrhythmic drugs. pp 440–462 In: 
[94]). However, this therapeutic range was developed using suppression of ventricular 
premature depolarizations as an endpoint, rather than efficacy for the management of AF. A 
relationship between serum flecainide concentrations and efficacy for prophylaxis or 
management of AF, particularly that occurring after noncardiac thoracic surgery, has not 
been established. Serum flecainide concentration monitoring for prophylaxis or treatment of 
AF after noncardiac thoracic surgery is not warranted.
3.5. Key limitations of drugs
3.5.1. Pulmonary toxicity: A primary concern regarding the administration of intravenous 
amiodarone following lung resection is pulmonary toxicity, specifically adult respiratory 
distress syndrome (ARDS). This concern was prominently identified by Van Mieghem et. 
al. [42], who initiated a study to determine the comparative effectiveness of amiodarone, 
verapamil, or placebo for prevention of AF after pulmonary resection. The study was 
terminated prematurely due a high incidence of ARDS in amiodarone-treated patients, 
specifically in patients who had undergone pneumonectomy. At the time of discontinuation 
of the amiodarone arm, the drug had been administered to 32 patients, of whom 21 had 
undergone lobectomy and 11 had undergone pneumonectomy. No patients who underwent 
lobectomy developed amiodarone-associated ARDS associated. In contrast, 3 of 11 patients 
(27%) in the amiodarone group who underwent pneumonectomy developed ARDS. The 
investigators recommended avoiding amiodarone administration for patients undergoing 
pulmonary resection.
Other investigators have administered intravenous amiodarone to patients undergoing lung 
surgery without adverse effects. In a prospective, randomized, unblinded amiodarone 
prophylaxis [95], the incidence of ARDS among the 65 amiodarone-treated patients (of 
whom n =40 underwent lobectomy, n=8 underwent bilobectomy, and n=17 underwent 
pneumonectomy) was 0%. Barbetakis et. al. [96] administered intravenous amiodarone to 43 
patients for treatment of AF after lung resection. No patients developed ARDS; n=21 of 
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these patients underwent pneumonectomy. Riber et. al. [97] conducted a randomized, 
prospective, double-blind placebo-controlled study of amiodarone for prevention of AF 
following lung resection. Only 2 patients of the 122 who received amiodarone underwent 
pneumonectomy; the remainder underwent right side lobectomy or bilobectomy. No patients 
in this study developed ARDS or any pulmonary toxicity.
One potential difference in patients undergoing pneumonectomy in the Van Miegham study 
([42] compared to these more recent trials [95]–[97] include the cumulative intravenous 
amiodarone dose administered. In the Van Mieghem study, intravenous amiodarone was 
administered as a bolus of 150 mg over 2 minutes, followed by a continuous infusion of 
1200 mg over 24 hours for 3 consecutive days, for a possible cumulative intravenous 
amiodarone dose of 3750 mg. The three patients who developed amiodarone-induced ARDS 
received cumulative intravenous amiodarone doses of 2150, 3750, and 3350 mg before 
discontinuation of therapy. In the more recent studies, patients received a cumulative 
intravenous amiodarone dose of 1050 mg, after which oral amiodarone was initiated [95], or 
a loading dose of 300 mg intravenous amiodarone before switching to oral amiodarone [97]. 
In the Barbetakis study [96], intravenous amiodarone was administered as a loading dose of 
5 mg/kg over 5 minutes, followed by 15 mg/kg for an undefined time period. In addition, in 
the Van Miegham study, the three patients who developed amiodarone-associated ARDS 
underwent right-sided pneumonectomy, which is associated with a higher risk of 
postoperative ARDS than other types of lung surgery.
Overall, administration of amiodarone at the dose shown to be effective by Riber et al. (300 
mg intravenous loading dose followed by 600 mg orally twice daily for 5 days) appears to 
be safe and effective for prevention of AF following pulmonary resection [97].
3.5.2. QT interval prolongation/torsades de pointes: A number of drugs that may be used 
for prophylaxis or management of postoperative AF may cause QT interval prolongation, 
and therefore pose a risk for the life-threatening polymorphic ventricular arrhythmia known 
as torsades de pointes (TdP) (Tisdale JE. Ventricular arrhythmias. pp 485–515 – In: [98]). 
Drugs that prolong the QT interval are generally those that inhibit IKr, and include 
amiodarone, procainamide, dofetilide, dronedarone, ibutilide, sotalol, and quinidine. A 
Bazett’s-corrected QT (QTc) interval > 500 ms markedly increases the risk for drug-induced 
TdP [99]. Patients receiving a drug that prolongs the QTc interval should have a QTc 
interval measured from a rhythm strip or 12-lead ECG at least once daily during therapy. In 
addition, since the occurrence of TdP is highly dependent on the presence of other risk 
factors (female sex, hypokalemia, hypomagnesemia, hypocalcemia, bradycardia, heart 
failure, elevated serum drug concentrations) (Tisdale JE. Ventricular arrhythmias. pp485–
515 In: [98]; [99]), modifiable risk factors should be corrected. Serum potassium, 
magnesium and calcium concentrations should be maintained in the normal range. Drug 
interactions leading to elevated concentrations of a QT interval-prolonging drug should be 
avoided. Doses of renally eliminated QT interval prolonging drugs (dofetilide, 
procainamide, sotalol) should be appropriately adjusted for declining kidney function. In 
addition, concomitant therapy with other QT interval-prolonging drugs, particularly 
noncardiovascular QT interval-prolonging drugs (fluoroquinolone and macrolide antibiotics, 
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azole antifungal agents, antidepressants, antipsychotics, many others) (Tisdale JE. 
Ventricular arrhythmias. pp 485–515 In: [98]) should be avoided or performed cautiously.
3.5.3. Hypotension: Several drugs administered intravenously for prophylaxis or 
management of postoperative AF may cause hypotension, including diltiazem, esmolol, 
metoprolol, procainamide, and amiodarone. Drug-associated hypotension is more likely to 
occur when patients are volume-depleted, which is often the case following thoracic surgery. 
In the post-coronary artery bypass graft population with AF, hypotension associated with 
intravenous diltiazem was more likely when the pretreatment systolic blood pressure was < 
115 mm Hg [100].
3.5.4. Bradycardia: Drugs used for ventricular rate control can also result in bradycardia 
through inhibition of sinus node function or AV nodal conduction. These drugs include 
amiodarone, propafenone, flecainide, esmolol, metoprolol, sotalol, and diltiazem (Tisdale 
JE. Supraventricular arrhythmias. pp 485–515 In: [98]). The risk is higher when 
combinations of sinus node or AV node-inhibiting drugs are used.
3.5.5. Exacerbation of heart failure with reduced left ventricular ejection fraction: Several 
drugs used for prophylaxis or treatment of postoperative AF possess negative inotropic 
activity and are contraindicated in patients with heart failure with reduced left ventricular 
ejection fraction. These drugs include diltiazem, procainamide, propafenone, and flecainide.
4. Prevention strategies and their efficacy (figure 1)
Recent evidence suggest that some prevention strategies (avoiding beta blockade withdrawal 
for those chronically on those medications, correction of serum magnesium when abnormal) 
maybe effective for all patients for reducing the incidence of POAF. By surveying the 
AATS membership, we also found that many of these strategies are currently underutilized.
RECOMMENDATIONS
4.1. Recommended prevention strategies for all patients
Class I
4.1.1. Patients taking β-blockers prior to thoracic surgery should continue them in the 
postoperative period to avoid β-blockade withdrawal [3], [26], [29], [101]–[106]. (LOE 
A)
Class IIb
4.1.2. Intravenous magnesium supplementation may be considered to prevent 
postoperative AF when serum magnesium level is low or it is suspected that total body 
magnesium is depleted [29], [35], [100], [106], [107]. (LOE C)
Class III
4.1.3. Digoxin should not be used for prophylaxis against AF [2], [29], [108]–[110]. 
(LOE A)
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4.1.4. Catheter or surgical pulmonary vein isolation (at the time of surgery) is not 
recommended for prevention of POAF for patients who have no prior history of AF 
[111]. (LOE C)
4.1.5. Complete or partial pulmonary vein isolation at the time of (even bilateral) lung 
surgery should not be considered for prevention of POAF, as it is unlikely to be 
effective [15], [26], [96], [104], [106], [111]–[114]. (LOE B)
For those patients at elevated risk for the development of POAF, preventive administration 
of medications (diltiazem or amiodarone) may be reasonable. However, these strategies may 
not be useful for all thoracic surgical patients.
4.2. Recommended prevention strategies for intermediate to high-risk patients
Class IIa
4.2.1. It is reasonable to administer diltiazem to those patients with preserved cardiac 
function who are not taking β-blockers preoperatively in order to prevent POAF [2], 
[17], [95], [97], [115], [116]. (LOE B)
4.2.2. It is reasonable to consider the postoperative administration of amiodarone to 
reduce the incidence of POAF for intermediate and high risk patients undergoing 
pulmonary resection [2], [27], [42], [110], [117]. (LOE A)
Class IIb
4.2.3. Postoperative administration of intravenous amiodarone may be considered to 
prevent POAF in patients undergoing esophagectomy [3], [15], [17], [26], [29], [42], 
[95], [97], [104], [106], [116], [118], [119]. (LOE B)
4.2.4. Atorvastatin may be considered to prevent POAF for statin naïve patients 
scheduled for intermediate and high risk thoracic surgical procedures [3], [26], [29], 
[104], [106], [120]–[122]. (LOE C)
4.3. Recommended prevention strategies for the highest-risk patients
Class IIb
4.3.1. Left atrial appendage excision may be considered at the time of extensive left 
lung surgery for patients with preexisting AF who are considered too high of a risk for 
anticoagulation in the perioperative period [2], [29], [123]. (LOE C)
REASONING
4.4. Prevention of postoperative AF: Atrial fibrillation, the most common sustained 
arrhythmia after pulmonary and esophageal surgery, is associated with longer intensive care 
unit and hospital stays, increased morbidity and mortality and higher utilization of 
healthcare resources [6], [30]. POAF also represents a major potentially preventable adverse 
outcome. A number of randomized controlled studies and meta-analyses have examined the 
efficacy of a variety of agents including antiarrhythmics, β-blockers and novel agents such 
as magnesium and statins, to prevent the development of POAF in patients undergoing 
thoracic surgery. However, it should be appreciated that there is a dearth of data indicating 
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that prophylactic therapy for AF improves outcomes after thoracic surgery, e.g., stroke and 
reduces length of hospital stay and many of the recommendations are extrapolated from the 
cardiac surgery arena.
The recommendation to avoid withdrawal of β-blockers in all patients undergoing thoracic 
surgery is mainly derived from the cardiac surgery literature. Nattel et al. [101] showed that 
abrupt propranolol withdrawal was associated with increased sensitivity to isoproterenol, 
and a large meta-analysis of randomized studies confirmed that acute withdrawal of β-
blockers prior to cardiac surgery increases the risk of developing POAF [105]. There are 
only limited data supporting the role of prophylactic β-blockers in patients undergoing 
thoracic surgery [102], [103]. While both of these randomized studies showed a reduction in 
POAF, there was a high incidence of hypotension and bradycardia that limited the use of β-
blockers in the perioperative setting [124]. There remains controversy in the recent literature 
as to whether to initiate perioperative β-blockade in patients who are not already taking 
them. At recommended doses aimed at achieving a target heart rate, β-blockers may cause 
significant postoperative hypotension and stroke related mortality [124]. In randomized 
controlled trials diltiazem has not been associated with perioperative hypotension. The 
ability of diltiazem to reduce AF after thoracic surgery is moderate [27].
To date the best evidence for efficacy of AF prevention in general thoracic surgery patients 
has been with amiodarone. An important issue with any prevention efforts is the acceptance 
of a recommended medication by the responsible surgical team, particularly with a drug like 
amiodarone that has potential for side effects. The antiarrhythmic mechanism of amiodarone 
combines varying degrees of class III antiarrhythmic activity, β-blockade and calcium 
channel antagonism. Slower postoperative heart rates with short term-use and greater than 
moderate efficacy in reducing AF may result in wider physician acceptance of amiodarone, 
although concerns regarding rare reports of pulmonary toxicity with right lung resection or 
lung transplantation may moderate its use (discussed in more detail in Section 3 above).
4.5. Pharmacological Therapies to Prevent POAF
4.5.1. Amiodarone
Efficacy: Tisdale et al. [95] showed that amiodarone 1.05 gm given by continuous IV 
infusion over the first 24h after pulmonary resection and then 400 mg orally twice daily for 
up to 6 days, reduced the rate of POAF requiring treatment, 9/65 (14%) in comparison to 
21/65 (32%), in an untreated control group. The same investigators in a similar study [17] 
showed that continuous infusion of amiodarone 43.75 mg/h for 96 hours (total dose 4200 
mg) was associated with a lower POAF rate of 6/40 (15%) in patients undergoing 
esophagectomy when compared to 16/40 (40%) in an untreated control group. The largest 
trial to date by Riber et al. [97] used a randomized, double-blind, placebo-controlled design 
of amiodarone given by loading 300 mg IV immediately when stable after surgery followed 
by 600 mg orally twice daily for up to 5 days. They showed that amiodarone-treated patients 
had a rate of POAF (lasting > 5 min) of 9% (11/122), compared to placebo controls who had 
a rate of 32% (38/120). A final study of patients undergoing pulmonary resection 
randomized 2 groups of patients in a prospective, double-blind design to either amiodarone 
(postoperative IV loading 5 mg/kg, then 15 mg/kg for 48 h IV infusion) or magnesium 
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sulfate (preoperative loading of 80 mg/kg and then 8 mg/kg/h for 48 h IV infusion after 
surgery) [116]. This study showed that the incidence of POAF (lasting >30 sec) was 10% 
(21/219) with amiodarone and 13% (27/219) with magnesium. None of these studies 
reported any serious adverse effects due to amiodarone except occasional bradycardia.
Safety: In the non-surgical population it is commonly accepted that amiodarone-related 
pulmonary toxicity does not occur with short-term (<1 month) exposure. Concerns over 
amiodarone-related perioperative pulmonary toxicity were raised two decades ago in a small 
randomized study that was interrupted early because 3 right-sided pneumonectomy patients 
out of a total of 11 patients that received amiodarone for prevention of POAF developed 
acute respiratory distress syndrome (ARDS), whereas none of the 21 patients undergoing 
lobectomy and exposed to amiodarone developed this complication [42]. The authors 
acknowledged that right-sided pneumonectomy in itself was a well-established risk for 
ARDS, but nevertheless cautioned on the use of amiodarone for AF prevention after 
pulmonary resection. Since then a number of observational and more recent prospective 
randomized trials failed to find a link between use of amiodarone for AF prevention and 
ARDS immediately after pulmonary resection [17], [95], [97], [116], [118]. A number of 
other studies used amiodarone for acute treatment of AF following general thoracic surgery, 
and none of these reported amiodarone-related pulmonary toxicity. Of 3 retrospective 
studies describing risk and treatment of AF after lung transplant, only 1 study [119] reported 
an association of pulmonary toxicity with amiodarone use and cautioned on the routine use 
of amiodarone after lung and heart-lung transplants [15], [119].
4.5.2. Diltiazem
Efficacy: A meta-analysis of randomized controlled trials that evaluated calcium channel 
blockers given immediately before, during or after coronary artery bypass (CABG) surgery 
or valve surgery showed that these drugs reduced rates of myocardial injury, and 
supraventricular tachycardia (SVT) [117]. In patients undergoing thoracic surgery there have 
been 3 prospective randomized trials of nondihydropyridine calcium channel antagonists for 
the prevention of AF. Verapamil prophylaxis was used in a large, randomized, open-label 
study of patients undergoing lobectomy or pneumonectomy using somewhat aggressive 
loading (started within 1 hour of arrival in recovery, 10 mg over 10 minutes followed by 
0.375 mg/min over 30 minutes) and then by continuous infusion (0.125 mg/min for 3 days) 
dosing [40]. This regimen was associated with a non-significant reduction of AF from 15% 
(15/99) in placebo patients to 8% (8/100) respectively. In a small randomized, open-label 
study of patients undergoing standard or intrapericardial pneumonectomy diltiazem 
prophylaxis was associated with reduced overall incidence of SVT in comparison to digoxin 
treated patients (0/21 vs. 8/25, P<0.005, respectively [110]). In a larger follow-up, 
randomized, double-blind, placebo controlled study of patients undergoing lobectomy or 
pneumonectomy, diltiazem started within 1 hour of arrival in recovery, 0.15 mg/kg (loading 
while patient was fasting then 120 mg orally twice a day for 14 days) reduced the rates of 
postoperative atrial arrhythmias in comparison to placebo, (25/167 [15%] vs. 40/163 [25%] 
respectively, P=0.03) [27].
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Safety: With the doses described in a randomized open-label study of verapamil given early 
after lobectomy or pneumonectomy, 14% of the patients experienced hypotension and 9% 
had bradycardia requiring temporary interruption of the drug infusion [40]. In contrast, mild 
transient hypotension was reported in 4% (6/163) of diltiazem treated patients especially 
early after surgery with resumption of diltiazem therapy soon thereafter [27].
4.5.3. Novel Therapies to Prevent Postoperative AF: Inflammation and oxidative stress 
play an important role in the pathogenesis of AF [125]. A number of studies have examined 
the role of statin therapy in preventing POAF. One of the largest (n=200) randomized 
studies evaluated the role of atorvastatin, given 7 days before and 7 days after cardiac 
surgery. Those patients who received the statin demonstrated a 22% reduction in incidence 
of POAF. Amar et al. [120] conducted a prospective study of 131 patients undergoing major 
lung or esophageal surgery to evaluate the relationship of C-reactive protein (CRP) and 
POAF. A secondary analysis in this study showed that in the subset of patients receiving 
preoperative statins the risk of developing AF was almost three-fold lower than in those not 
taking them. Two meta-analyses of randomized studies examining prophylactic statin 
therapy was performed that involved over 2200 patients [121], [122]. These studies 
supported the role of statins in preventing POAF in statin-naïve patients undergoing high-
risk cardiac and non-cardiac surgery or after acute coronary syndromes. Additional 
randomized placebo controlled studies will be required before statin therapy can be 
recommended as a Class I or IIa indication to prevent POAF in statin-naïve patients 
undergoing moderate to high-risk lung surgery. As in other patients undergoing non-cardiac 
surgery, most physicians continue statin therapy preoperatively to avoid withdrawal.
There is strong evidence supporting the use of magnesium supplementation to prevent 
POAF in patients undergoing cardiac surgery [107]. In the only prospective, unblinded 
randomized controlled trial (n = 200) in patients undergoing thoracic surgery, Terzi et al. 
[35] demonstrated that the incidence of postoperative atrial tachyarrhythmias, mainly AF, 
was reduced from 23% to 11% in those patients treated with an IV infusion of magnesium 
during the perioperative period.
Three large randomized clinical trials have clearly demonstrated that prophylaxis with 
digoxin does not prevent and may in fact increase the incidence of POAF in patients 
undergoing all types of thoracic surgery [108]–[110]. While, acute digoxin loading may be 
beneficial in controlling rapid ventricular rates during AF in patients with hypotension, there 
is no place for digoxin prophylaxis in patients undergoing thoracic surgery.
4.5.4. Surgical Prevention Strategies: Cardiac surgery patients with pre-existing AF who 
undergo surgical pulmonary vein isolation (PVI) and receive additional biatral linear lines of 
block may achieve a 75–85% freedom from AF at 6–12 months, and the procedure adds on 
average an additional 9 minutes to the surgery, without perceptible safety risks, though 
possibly the patients have a slightly higher risk of needing a pacemaker during the early 
postoperative period [126]. Patients who undergo the equivalent of near complete PVI 
associated with bilateral lung transplantation have a very low incidence of AF 3–6 six 
months post procedure [111]. For patients with preexisting AF, who are known to tolerate 
poorly the arrhythmia or who have an increased bleeding risk on anticoagulants, two 
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questions arise: would PVI, bilateral or unilateral, help prevent perioperative AF, and would 
operative left atrial appendage exclusion lower perioperative thrombotic risk?
Multiple studies [111], [113], [114] have shown that the incidence of POAF is in the 20–
40% range even following double lung transplant, confirming the fact that this form of AF is 
related to inflammatory, mechanical, and autonomic factors, in addition to pulmonary vein 
triggers. Unilateral pulmonary vein isolation is not likely to be any more beneficial, and has 
a distinct disadvantage beyond the perioperative period [112].
Excision of the left atrial appendage can be performed safely, with efficacy rates 
approaching 87%, following a learning curve [123], but there are no studies that show a 
reduction in perioperative thrombotic events. The Left Atrial Appendage Occlusion Study is 
ongoing. Data from the Watchman [127] and Prevail trials cannot necessarily be 
extrapolated to operative left atrial appendage exclusion, and neither of these studies 
involved thoracotomy patients. Though the alteration in left atrial compliance and filling 
pressures following appendage exclusion may be small, the effects may be different in a 
lung population that may have a smaller atrial size, than in a cardiac valve surgery 
population.
5. Treatment strategies for POAF and their efficacy
The management of patients presenting with POAF requires different strategies depending 
on their hemodynamic stability. While some interventions are likely to benefit all patients 
(see 5.1), hemodynamically unstable patients will require urgent efforts for the restitution of 
sinus rhythm (section 5.2). However, for stable patients with POAF the emphasis shifts to 
rate control strategies (see detailed in 5.3) [2].
RECOMMENDATIONS
5.1. Management strategies recommended for all patients with new onset 
POAF (figure 2)
Class I
5.1.1. Reduce or stop catecholaminergic inotropic agents if hemodynamics allow. (LOE 
C)
5.1.2. Optimize fluid balance and maintain normal electrolyte levels. (LOE C)
5.1.3. Evaluate the presence of and treat all possible correctable triggering factors. 
These may include bleeding, pulmonary embolism, pneumothorax, pericardial 
processes, airway issues, myocardial ischemia, or infection/sepsis. (LOE C)
Class IIb
5.1.4. Cardiology consultation may be useful for those patients (LOE C) who:
5.1.4.1. Develop recurrent or refractory POAF.
5.1.4.2. Develop a hemodynamically unstable condition.
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5.1.4.3. Are at high risk for stroke based on CHA2DS2-VASc score and will likely 
require longer-term anticoagulation.
5.1.4.4. Require a second-line anti-arrhythmic medication for stabilization.
5.1.4.5. Also develop acute kidney injury.
REASONING—For all patients with new onset POAF after thoracic surgery, consideration 
should be given to triggering causes. Although inflammation provoked by surgical 
procedures, patient risk factors for AF, and mechanical proximity of thoracic surgery 
procedures to cardiac structures are often sufficient to explain the occurrence of POAF, 
other triggers may need to be identified in patients with recurring, symptomatic, or 
refractory AF. These include bleeding, pulmonary embolism, pneumothorax, pericardial 
processes, airway issues, myocardial ischemia, or infection/sepsis. Minimization, weaning 
or discontinuation of catecholaminergic inotropic agents, if possible, optimization of fluid 
status, and correction of any electrolyte/metabolic disturbances may also facilitate 
restoration and maintenance of sinus rhythm.
As a general rule, although much, if not most, POAF is transient and largely limited to the 
postoperative period (2–6 weeks), consultation with a cardiologist or cardiac 
electrophysiologist may be useful, especially for patients with recurrent or refractory POAF. 
This is usually for three issues: management of rate control during AF; consideration of 
whether, when, and how to restore sinus rhythm; and consideration of anticoagulation. The 
first issue is usually not difficult to accomplish, and standard prophylactic use of diltiazem 
or β blockers usually insures that should POAF occur, ventricular rate control may be as 
simple as maintaining this therapy. However, tachy-brady syndrome may complicate efforts 
at rate control that may require alternative medical options, rhythm control strategies, or 
anti-bradycardic pacing. The second issue may be more complex, but decisions about if, 
when, and how to restore sinus rhythm often benefits from direct, nuanced cardiology and/or 
cardiac electrophysiology (EP) involvement. Such consultation can be useful in the selection 
and management of antiarrhythmic medications or in determining a need for permanent 
pacing. The third issue is probably the most important and a challenge particularly for 
patients at high risk for bleeding. Cardiologists may assist with management of patients at 
high risk for stroke needing longer term anticoagulation, unstable patients, or patients with 
acute kidney injury, which can worsen outcomes, including stroke, and limit antiarrhythmic 
and anticoagulant choices. Close interaction between the surgical team and the cardiology 
team should provide excellent, well considered anticoagulation decisions. In the end, the 
patient and thoracic surgical team will be well served by a close consultative relationship 
with the cardiologist.
RECOMMENDATIONS
5.2. Recommendations for the management of the hemodynamically unstable 
patient with new onset POAF (figure 3)
Class I
5.2.1. Emergent R-wave synchronized direct-current electrical cardioversion (DCC) is 
recommended for hemodynamically unstable patients and for patients with evidence of 
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acute myocardial ischemia or infarction. Signs of hemodynamic instability include: 
severe symptomatic hypotension, shock, or pulmonary edema. [2]–[4], [29]. (LOE C)
5.2.1.1. For unstable patients with new onset POAF of less than 48-hour duration, 
emergent DC cardioversion is indicated and is acceptable to be performed prior to 
initiation of anticoagulation. [2], [3], [73]. (LOE C)
5.2.1.2. For unstable patients who undergo cardioversion more than 48 hours after the 
onset of AF, and who do not have an excessive bleeding risk or other 
contraindication, anticoagulation should be initiated as soon as possible and 
continued for at least 4 weeks [2], [3], [45]. (LOE C)
Class IIa
5.2.2. If initial DC cardioversion is unsuccessful or hemodynamically unstable AF 
recurs, the following steps can be useful:
5.2.2.1. Initiate rate and possible rhythm control therapy with intravenous esmolol, 
diltiazem, digoxin, or amiodarone while preparing for repeat DC cardioversion. (LOE 
C)
5.2.2.2. Repeat DC cardioversion (more likely to be successful after initiating a 
rhythm control agent). (LOE C)
REASONING—Some patients with new onset AF are hemodynamically unstable, defined 
as AF associated with symptomatic severe hypotension, evidence of acute myocardial 
ischemia or infarction, or pulmonary edema/heart failure. For such patients, immediate 
electrical direct current (DC) cardioversion is recommended [2], [3]. Electrical 
cardioversion should be performed under deep conscious sedation with R-wave 
synchronized shocks. Cardioversion can be performed with biphasic or monophasic 
waveforms. However biphasic waveform shocks are preferred over monophasic waveforms, 
as the latter can require higher defibrillation energies for success. Anterior-posterior 
electrode patch positioning (e.g. R parasternal – L posterior or mid-low sternal -posterior) 
may produce a more successful defibrillation vector for cardioversion of AF than anterior 
only (e.g. R parasternal to anterior or anterolateral apex) positions. If DC cardioversion 
using one defibrillator patch location fails, the alternate patch position should be used.
If AF duration in the unstable patient is less than 48 hours, cardioversion can be performed 
prior to initiation of anticoagulation [2], [3], [45]. However, for patients with AF of more 
than 48 hours duration who become hemodynamically unstable, there is a higher risk of left 
atrial or atrial appendage thrombus that could dislodge at the time of or in the days 
following cardioversion in the absence of anticoagulation. Thus, it is recommended that for 
these patients, in the absence of contraindications (such as excessive bleeding risk or known 
heparin sensitivity) heparin be administered concurrently with the cardioversion, and used 
during transition to an oral anticoagulant. The oral anticoagulant should be provided for at 
least 4 weeks after cardioversion, as for patients undergoing elective cardioversion [2], [3], 
[45].
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Should initial cardioversion be unsuccessful or should hemodynamically unstable AF recur, 
repeat cardioversion can be attempted. To facilitate this, and while preparing for repeat 
cardioversion, attempts at pharmacologic rate or rhythm control may be considered with 
such drugs as IV amiodarone, esmolol, diltiazem, or digoxin. When hypotension is a 
problem, IV digoxin may be considered. However, should pharmacologic management fail, 
repeat electrical cardioversion is recommended.
RECOMMENDATIONS
5.3. Recommendations for the management of the hemodynamically stable patient with 
new onset AF (figure 4 and 5): Primary treatment goal is rate control with rhythm control 
as secondary option.
Class IIa
5.3.1. It is reasonable to manage stable, well-tolerated new onset POAF with a rate 
control strategy. [2], [26], [106], [128]–[130]. (LOE C)
5.3.2. Rhythm control with antiarrhythmic drugs and/or DC cardioversion can be useful 
for patients with hemodynamically stable new onset POAF who have recurrent or 
refractory POAF, continued symptoms, intolerance to rate control medications, or 
ventricular rates that cannot be adequately controlled. [2], [128], [130]. (LOE C)
5.3.3. A rhythm control approach with pharmacologic or DC cardioversion is 
reasonable for patients with new onset POAF nearing 48 hours in duration, who are at 
high risk for bleeding, in order to avoid anticoagulation that would be otherwise 
indicated for AF persisting longer than 48 hrs. (LOE C)
REASONING—Similar to AF occurring after cardiac surgery, new onset POAF after 
thoracic surgery is often self-limited with patients returning to sinus rhythm within 4–6 
weeks after surgery regardless of a rate or rhythm control strategy. An observational study 
of 30 patients with new onset AF after lung resection and no history of heart rhythm disease 
reported that sinus rhythm was restored within the first 24 hours in 70% of patients treated 
with diltiazem, and in 67% of patients treated with amiodarone; after 48 hrs, 80% in both 
groups were in sinus rhythm [26]. AF recurred in 11 (37%), but 10 converted after IV 
treatment. In a retrospective review of 41 patients who developed POAF after lung 
resection, 98% of AF disappeared within a day of discharge and 85.4% required 
pharmacologic management, but none required electrical cardioversion [106]. Sinus rhythm 
was restored after loading with digoxin in 80%, 11.5% after amiodarone, and 8.5% with 
both. All patients except one were discharged in sinus rhythm. In another study of aortic 
surgery in 211 patients, 22 developed POAF; 16 spontaneously converted to sinus rhythm, 2 
converted chemically and 1 electrically, and 3 continued in AF at discharge, but all were in 
sinus rhythm documented with an ECG a mean of 14 months after discharge [129]. Thus, 
most patients with new POAF after thoracic surgery can be expected to return to sinus 
rhythm regardless of a rate or rhythm control strategy.
Rate vs. rhythm control strategies have been studied in randomized trials for non-POAF 
[131]–[135]. The largest of these, the Atrial Fibrillation Follow-Up Investigation of Rhythm 
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Management (AFFIRM) study [131], was powered to detect a difference in overall 
mortality, but showed no difference between a strategy of rhythm vs. rate control in the 
primary endpoint of all-cause mortality, with a slight trend toward better survival in the rate 
control arm. Secondary analyses demonstrated no differences in quality of life [136], 
although other sub-analyses demonstrated better mortality in patients in sinus rhythm or on 
warfarin [137], and a functional status sub-study demonstrated better NYHA functional 
class in the rhythm control arm and longer 6 minute walk test distances in patients in sinus 
rhythm [138].
However, there are no randomized trials studying rate vs. rhythm control strategies for 
POAF after thoracic surgery, and there have been only small, randomized pilot trials 
performed after cardiac surgery. In a randomized pilot study by Lee, et al, of 50 patients 
with POAF after cardiac surgery, 27 were randomized to antiarrhythmic drug therapy ± 
electrical cardioversion and 23 to a rate control approach [128]. The endpoints were length 
of stay and incidence of recurrent AF. There was no significant difference in time to 
conversion to sinus rhythm. With multivariable Cox analyses, adjusting for other covariates, 
there was a trend toward a reduction in time from treatment to sinus rhythm in the 
antiarrhythmic arm (P=0.08), as well as a lower length of stay (P=0.05). At termination, in 
the rate control arm, 91% were in sinus rhythm, and in the antiarrhythmic arm 96% were in 
sinus rhythm. The majority were in sinus rhythm after 2 months. In a randomized pilot study 
by Soucier, et al. [130], in stable patients with new AF after cardiac surgery, 42 patients 
were randomized to propafenone 600 mg dose (N=20) vs. ibutilide 1 mg IV up to 2 doses 
(N=10) vs rate control (N=12). At 24 hours 0, 65 and 34% of patients in the ibutilide 
(P=0.01), propafenone (P>0.05), and rate control arms remained in AF. Ibutilide decreased 
AF duration, but recurrence rates were 90%, 41%, and 58% in the three arms (P>0.05). The 
3 patients who did not convert all received propafenone. There were no differences in length 
of stay or rhythm at discharge. These two small prospective randomized pilot studies thus 
showed few differences between rate and rhythm control strategies.
The absence of significant differences in the small rate vs. rhythm control studies of AF 
after cardiac surgery justifies use of either rate or rhythm control strategies in patients with 
new onset POAF who are hemodynamically stable. However, the high rate of spontaneous 
conversion to sinus rhythm in the first 24 hours after onset of POAF makes it reasonable to 
opt for an initial rate control approach in stable patients, especially over the first 24 hours. 
Since anticoagulation is generally recommended in patients with AF lasting longer than 48 
hours, the higher risks of postoperative bleeding with anticoagulation can also justify a 
rhythm control approach in patients with new postoperative AF that persists longer than 24 
hrs despite a rate control approach. A rhythm control approach with pharmacologic or 
electrical cardioversion may also be reasonable in patients whose ventricular rates cannot be 
adequately controlled, or in patients who either do not tolerate AV nodal blockers to control 
ventricular rate or who remain symptomatic or hemodynamically compromised despite 
control of the ventricular rate.
For the patient with stable hemodynamics and minimal symptoms, a trial of rate control for 
the first 24 hours is generally recommended, as a high proportion will convert to sinus 
rhythm within 24 hours using rate control or rhythm control agents. Inotropes should be 
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stopped or reduced, if clinically acceptable, fluid balance optimized, and normal electrolyte 
balance maintained. Rate control may be achieved with IV esmolol or metoprolol, IV 
diltiazem, IV verapamil (though this carries more risk for hypotension than diltiazem), 
digoxin (especially if there is hypotension or heart failure), or IV amiodarone. If AF persists, 
DC cardioversion may be considered within 48 hrs of onset; anticoagulation would be 
indicated for AF persisting >48 hrs. Alternatively, if the AF is well tolerated, the patient 
could be started on anticoagulation and rate control with plans for elective cardioversion in 
4–6 weeks. If AF is recurrent after cardioversion, antiarrhythmic therapy with repeat DC 
cardioversion can be continued with maintenance oral therapy for 4–6 weeks, or a rate 
control approach can be adopted with anticoagulation and plans for elective cardioversion if 
AF persists after 4–6 weeks (see figures 2, 4 and 5).
RECOMMENDATIONS
5.4. Medical management of patients with new onset POAF (figure 4 and 5)
5.4.1. Rate Control Recommendations
5.4.1.1. Intravenous administration of beta-blockers (e.g. esmolol or metoprolol) or 
nondihydropyridine calcium channel blockers (diltiazem or verapamil) is recommended 
to achieve rate control (heart rate ≤110 bpm) for patients who develop POAF with rapid 
ventricular response [2], [26], [28]. (LOE B)
5.4.1.2. Caution should be used with patients with hypotension, LV dysfunction, or 
heart failure [2], [26], [28], [29]. (LOE B)
5.4.1.3. Combination use of AV nodal blocking agents, such as beta-blockers (e.g. 
esmolol or metoprolol), nondihydropyridine calcium channel antagonists (e.g. diltiazem 
or verapamil), or digoxin, can be useful to control heart rates when a single agent fails 
to control rates of POAF. The choice should be individualized and doses modified to 
avoid bradycardia [2], [29]. (LOE B)
5.4.1.4. For patients with hypotension, heart failure or LV dysfunction, or when other 
measures are unsuccessful or contraindicated, intravenous amiodarone can be useful for 
control of heart rate. Amiodarone could result in conversion to sinus rhythm, and if it is 
initiated after 48 hours of AF, both a TEE when possible, to rule out LA/LAA 
thrombus, and full anticoagulation should be considered [3], [26], [29], [104], [106]. 
(LOE B)
5.4.1.5. For patients with heart failure, LV dysfunction or hypotension, intravenous 
digoxin may be considered for rate control of POAF [29], [100], [106]. (LOE B)
5.4.1.6. For patients with ventricular preexcitation (i.e. Wolff-Parkinson-White 
syndrome) and POAF, use of AV nodal blocking agents, such as beta-blockers (e.g. 
esmolol or metoprolol), intravenous amiodarone, nondihydropyridine calcium channel 
antagonists (e.g. diltiazem or verapamil), or digoxin, should be avoided [2], [29]. (LOE 
C)
REASONING—Achieving control of ventricular rates in AF is a first line approach to 
patients with POAF after thoracic surgery. This may be achieved with use of intravenous or 
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oral AV nodal blocking agents, but intravenous beta-blockers or nondihydropyridine 
calcium channel blockers (e.g. diltiazem, verapamil) can often achieve more rapid rate 
control than use of oral agents. Choice of agents is usually based on comorbidities. Beta-
blockers have often been first line therapy for ventricular rate control after cardiac surgery, 
and may be preferred over calcium channel blockers in patients with coronary disease. 
Calcium channel blockers are preferred in patients with bronchospasm limiting 
consideration of beta-blockers, but should be avoided in patients with heart failure or severe 
LV dysfunction. Diltiazem is often as effective as beta-blockers with less hypotension, can 
be titrated as a continuous infusion, and has a greater margin of safety than verapamil, which 
may be limited by hypotension.
The use of digoxin is generally less effective in the acute postoperative high 
catecholaminergic state, and it has a slower onset of action. But in the face of hypotension, 
digoxin may be the treatment of choice. Beta-blockers and calcium channel blockers have 
been shown to be more effective at controlling ventricular rates with shorter times to effect 
than digoxin. Tisdale, et al. [100] compared intravenous diltiazem (N=20) vs. digoxin 
(N=20). The endpoints included ventricular rate control, defined as a ≥20% decrease from in 
pretreatment ventricular rate, and postoperative length of stay. Intravenous diltiazem 
achieved rate control within a mean of 10 mins, compared to 352 mins with digoxin 
(P<0.0001). At 2 and 6 hours, successful rate control was higher in the diltiazem group, but 
by 24 hrs there was no difference, as conversion to sinus rhythm occurred in 55% on 
diltiazem and 65% on digoxin. There was no difference in postoperative length of stay. 
However, digoxin may be particularly useful in patients with heart failure, LV dysfunction, 
or hypotension, or in combination with other agents. The addition of digoxin might also 
facilitate a lower dose of beta-blockers or calcium channel blockers in patients with 
hypotension. Combination use of beta-blockers, calcium channel blockers, or digoxin can be 
attempted in patients with rapid rates refractory to monotherapy, but caution should be 
exercised with dosage modification to avoid hypotension and bradycardia, including pauses 
upon termination of AF.
It should be noted that in the presence of ventricular preexcitation (Wolff-Parkinson-White 
syndrome), AV nodal blocking agents, such as calcium channel blockers, beta-blockers, 
digoxin and intravenous amiodarone may potentiate rapid conduction through the accessory 
atrioventricular pathway due to removal of concealed conduction from the AV node. 
Digoxin may also shorten the AV node effective refractory period within the accessory 
pathway. For these patients AV nodal blocking agents should be avoided, and 
antiarrhythmic medication (intravenous ibutilide, amiodarone, or procainamide) considered.
Amiodarone has also been used for ventricular rate control. However, as its antiarrhythmic 
properties could lead to conversion of AF to sinus rhythm, caution should be exercised if 
amiodarone is initiated after 24–48 hours after the onset of AF, as there is a possibility that 
the AF could convert to sinus rhythm with the attendant risk of thromboembolism. In these 
circumstances, a TEE should be considered to exclude left atrial or left atrial appendage 
thrombi prior to initiation of amiodarone.
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Parameters for optimal control of ventricular rates during AF remain controversial. The 
RACE II study [28] evaluated a lenient (resting heart rate <110 bpm) versus strict (resting 
heart rate <80 bpm) rate control strategy in 614 patients with permanent AF. There was no 
difference in cardiovascular death, hospitalization for heart failure, stroke, systemic 
embolism, bleeding, and life-threatening arrhythmic events. It should be noted that the mean 
ventricular rate in the lenient-control group was 85 bpm and in the strict-control group 76 
bpm at the end of the follow-up period. Although this population is quite different from 
patients with new onset POAF, more lenient rate control (to HR ≤ 110 bpm) may be 
preferable to strict rate control in the postoperative setting when patients are prone to 
hemodynamic instability or hypotension. The normal metabolic response to surgery is 
associated with an increase in catecholamines, often manifested in sinus tachycardia in the 
early perioperative period and reflected in higher ventricular rates in AF.
There are no data to suggest efficacy for adding magnesium or potassium to facilitate 
conversion to sinus rhythm or to improve rate control after thoracic surgery. However, it 
seems reasonable to recommend maintaining normal levels.
RECOMMENDATIONS
5.4.2. Recommendations for the use of antiarrhythmic drugs (figure 6a and 
6b)
Class IIa
5.4.2.1. Restoration of sinus rhythm with pharmacologic cardioversion is reasonable in 
patients with symptomatic, hemodynamically stable POAF [5], [139]–[141]. (LOE C)
5.4.2.1.1. Intravenous amiodarone can be useful for pharmacologic cardioversion of 
POAF [15], [26], [96], [104], [106]. (LOE B)
5.4.2.2. It is reasonable to administer antiarrhythmic medications in an attempt to 
maintain sinus rhythm for patients with recurrent or refractory POAF [2], [115]. (LOE 
B)
5.4.2.2.1. Amiodarone, sotalol, flecainide, propafenone, or dofetilide can be useful to 
maintain sinus rhythm in patients with POAF, depending on underlying heart disease, 
renal status and other comorbidities (see below) [2]. (LOE B)
Class IIb
5.4.2.3. Flecainide or propafenone may be considered for pharmacologic cardioversion 
of POAF and maintenance of sinus rhythm if the patient has had no prior history of 
myocardial infarction, coronary artery disease, impaired LV function, significant LVH, 
or valvular heart disease that is considered moderate or greater. These agents may need 
to be combined with an AV nodal blocking agent [3], [26], [29], [104], [106]. (LOE C)
5.4.2.4. Intravenous ibutilide or procainamide may be considered for pharmacologic 
conversion of POAF for patients with structural heart disease and new onset POAF, but 
no hypotension or manifestations of congestive heart failure. Serum electrolytes and 
QTc interval must be within a normal range and patients must be closely monitored 
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during and for at least 6 hours after the infusion if either ibutilide or procainamide [3], 
[26], [29], [104], [106]. (LOE B)
5.4.2.5. Intravenous ibutilide or procainamide may be considered for patients with 
POAF and an accessory pathway [2], [29]. (LOE B)
Class III
5.4.2.6. Flecainide and propafenone should not be used to treat POAF in patients with a 
history of a prior myocardial infarction, coronary artery disease, and/or severe structural 
heart disease, including severe left ventricular hypertrophy, or significantly reduced left 
ventricular ejection fraction [3], [29]. (LOE B)
5.4.2.7. Dronedarone should not be used for treatment of POAF in patients with heart 
failure [2], [73]. (LOE B)
REASONING—For patients with symptomatic but hemodynamically stable AF after 
thoracic surgery, consideration should be given to restoring sinus rhythm with 
pharmacological cardioversion [139], Faniel:1983vl. [141]. While one study demonstrated a 
cardioversion rate of 86% with intravenous amiodarone in patients undergoing pulmonary 
resection for lung carcinoma [26], [96], a meta-analysis that included both medical and 
POAF suggested a slightly lower rate of conversion of 76% [15], [26], [96], [104], [106], 
[142]. The class IC antiarrhythmic drugs (flecainide, propafenone) may also be considered 
to restore and maintain sinus rhythm. Reisinger et al. [143] compared the efficacy and safety 
of intravenous flecainide vs. intravenous ibutilide in patients with recent onset AF and 
showed that the rate of cardioversion was similar (56% vs. 50%, P>0.05). However, it 
should be appreciated that the intravenous form of flecainide is not available in the U.S. and 
an oral loading dose of flecainide (and propafenone) would be required to restore sinus 
rhythm [96], [142]–[146]. It is usually customary to combine flecainide and propafenone 
with AV nodal blocking agents to prevent 1:1 atrial flutter and rapid ventricular conduction. 
Ibutilide is another antiarrhythmic drug that has moderate efficacy at restoring sinus rhythm 
[143]. However, it is only available in an intravenous form and it necessitates close 
monitoring of serum electrolytes and QTc. Patients must be monitored during and after 
intravenous ibutilide for at least 6 hours [2], [147].
For patients with recurrent symptomatic POAF, it is reasonable to not only restore sinus 
rhythm but also consider maintaining sinus rhythm with antiarrhythmic drugs. While many 
membrane active drugs (amiodarone, sotalol, flecainide, propafenone, dofetilide or 
dronedarone) have been shown to prevent recurrences of AF in both POAF and in the non-
operative setting with variable efficacy, the choice of antiarrhythmic drug is very much 
governed by associated comordibities, such as structural heart disease and impaired renal 
function. Overall, the selection of antiarrhythmic drugs to maintain sinus rhythm after 
thoracic surgery is similar to that outlined in the recently published AF guidelines for the 
management of non-operative AF [2], [3]. A review of antiarrhythmic drugs, their side 
effects and interactions are outlined in Section 3 and in tables 6 and 7.
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5.5. Non-pharmacologic management of POAF
5.5.1. Recommendations for DC cardioversion for stable patients with POAF
5.5.1.1. DC cardioversion is recommended for symptomatic or relatively 
hemodynamically compromised patients with POAF if they do not respond promptly to 
pharmacological attempts to control rapid ventricular rates [2], [3], [45]. (LOE C)
5.5.1.2. DC cardioversion is recommended for patients without hemodynamic 
instability when symptoms of AF are unacceptable to the patient or when rapid 
ventricular rates do not respond to pharmacological measures [2], [6], [30]. (LOE C)
5.5.1.3. DC cardioversion can be a reasonable alternative to pharmacological 
cardioversion [139]–[141]. (LOE C)
5.5.1.4. Pretreatment with an antiarrhythmic drug can be useful to enhance the success 
of DC cardioversion (as described in 5.2.2.1.1.) and to prevent recurrent AF [2]. (LOE 
B)
5.5.1.5. Caution is advised for patients with preoperative or unknown sinus node 
dysfunction or with patients receiving significant doses of rate controlling medications, 
as significant pauses can occur after DC cardioversion. For those patients external 
pacing may be required and should be readily available. (LOE C)
5.5.1.6. It is reasonable to repeat DC cardioversion, following administration of an 
antiarrhythmic medication, for patients who relapse to AF after successful cardioversion 
[2], [45]. (LOE C)
5.5.1.7. Patient and physician preference are reasonable considerations for selecting DC 
cardioversion [2], [101]–[103], [105]. (LOE C)
5.6. Recommendations for prevention of thromboembolism for patients with 
stable atrial fibrillation/flutter undergoing DC cardioversion
Class I
5.6.1. For stable patients with POAF of 48-hours duration or longer, anticoagulation 
(with warfarin for INR 2.0 to 3.0, a novel oral anti-coagulant [NOAC] or LMWH) is 
recommended for at least 3 weeks prior to and 4 weeks after cardioversion, regardless 
of the method (electrical or pharmacological) used to restore sinus rhythm [2], [35], 
[107]. (LOE B)
Class IIa
5.6.2. During the first 48 hours after the onset of POAF, the need for anticoagulation 
before and after DC cardioversion may be based on the patient’s risk of 
thromboembolism (CHA2DS2-VASc score; figures 9 and 10) balanced by the risk of 
postoperative bleeding [2], [108]–[110]. (LOE C)
5.6.3. For POAF lasting longer than 48 hrs, as an alternative to 3 weeks of therapeutic 
anticoagulation prior to cardioversion of POAF, it is reasonable to perform TEE in 
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search of thrombus in the LA or LA appendage, preferably with full anticoagulation at 
the time of TEE in anticipation of DC cardioversion after the TEE [111], [148], [149]. 
(LOE B)
5.6.3.1. For patients with no identifiable thrombus, DC cardioversion is reasonable 
immediately after the TEE exam if therapeutic anticoagulation is achieved. 
Anticoagulation should continue for at least 4 additional week though the benefits 
must be weighed against the risk of bleeding [2], [111]–[114]. (LOE C)
5.6.4. For POAF lasting longer than 48 hrs in patients who are not candidates for TEE 
(e.g. post-esophageal surgery), an initial rate control strategy combined with therapeutic 
anticoagulation using warfarin (aiming for INR 2.0 to 3.0), a direct thrombin inhibitor 
(e.g. dabigatran), factor Xa inhibitor (e.g. rivaroxaban, apixaban), or LMWH is 
recommended for at least 3 weeks prior to and 4 weeks after cardioversion. (LOE C).
5.6.5. Anticoagulation recommendations for cardioversion of atrial flutter are similar to 
those for atrial fibrillation [2], [17], [95], [97], [116]. (LOE C)
Class III
5.6.6. For patients with an identified thrombus, cardioversion should not be performed 
until a longer period of anticoagulation is achieved (usually at least 3 weeks) and in 
accordance with established AF guidelines [2], [27], [42], [110], [117], [148], [149]. 
(LOE B)
REASONING—Electrical DC cardioversion is recommended for new onset POAF that is 
associated with unstable hemodynamics. DC cardioversion should be performed under deep 
conscious sedation with R-wave synchronized shocks. Biphasic waveform shocks are 
preferred over monophasic waveforms, which can require higher defibrillation energies for 
success.
Commonly, rate control is attempted for at least the first 24 hours, as up to 80% of patients 
may spontaneously convert with rate control alone (see rate control agents in table 6). For 
patients with persistent AF and significant symptoms despite attempts to control ventricular 
response, pharmacologic or electrical cardioversion can be considered. When AF nears 48 
hours in duration, such pharmacologic or electrical cardioversion may be reasonable, 
particularly in patients who are at high risk for bleeding, to avoid anticoagulation that would 
otherwise be indicated for AF persisting longer than 48 hrs (see Section 5.3.1.). Pretreatment 
with an antiarrhythmic drug (see in table 7) can be useful to enhance the success of electrical 
cardioversion and prevent recurrent AF. However, this requires some caution if the 
preoperative or current status of sinus node function is unknown. If sinus node dysfunction 
is present, since most antiarrhythmic drugs suppress sinus node function, successful 
cardioversion can be associated with initial prolonged asystole and/or prolonged 
hypotension. In such patients, readiness for external pacing should be anticipated. If the 
status of sinus node function is unknown, proceeding to electrical cardioversion without 
administration of a pre-cardioversion antiarrhythmic drug is reasonable.
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For recurrent AF after initial conversion to sinus rhythm, cardioversion may be considered, 
often after initiation of an antiarrhythmic drug to prevent further recurrences. For recurrent 
or refractory AF, evaluation for potential triggering causes should be investigated. These 
include bleeding, pulmonary embolism, pneumothorax, pericardial processes, airway issues, 
myocardial ischemia, infection, sepsis, or use of catecholaminergic inotropes. Should AF 
manifest as frequent paroxysms with intervening episodes of sinus rhythm, electrical 
cardioversion is not recommended, unless AF becomes persistent, as AF is likely to recur 
after cardioversion. In these situations, an antiarrhythmic drug may be beneficial.
For AF >48 hrs in duration, anticoagulation with warfarin (INR 2.0 to 3.0), a direct thrombin 
inhibitor (e.g. dabigatran), factor Xa inhibitor (e.g. rivaroxaban, apixaban), or low molecular 
weight heparin is recommended for at least 3 weeks prior to and 4 weeks after 
cardioversion, as in other patients with AF. As an alternative to anticoagulation prior to 
cardioversion of AF, a TEE may be performed in search of thrombus in the LA or LAA. It is 
preferable to perform the TEE on full anticoagulation with heparin or therapeutic levels of 
oral anticoagulants, and then to perform electrical or pharmacologic cardioversion 
immediately afterwards on therapeutic anticoagulation. This is preferred over performing a 
TEE while off anticoagulation or on sub-therapeutic anticoagulation, as a thrombus may 
form between the time of TEE and full anticoagulation. In patients with no identifiable 
thrombus, cardioversion is reasonable immediately after TEE on therapeutic anticoagulation 
with anticoagulation continued for at least 4 weeks afterwards, as for patients undergoing 
elective cardioversion. For patients with an identified thrombus, cardioversion should be 
deferred until a longer period of anticoagulation is achieved and in accordance with 
established AF guidelines. The TEE-guided cardioversion approach is supported by results 
of the ACUTE trial, which enrolled 1222 patients with AF of greater than 2 days duration 
and randomized them to TEE-guided cardioversion vs warfarin anticoagulation for at least 3 
weeks prior to cardioversion. There was no difference between groups in the rate of embolic 
events, but the rate of hemorrhagic events was lower in the TEE group. It should be noted 
that exclusion of left atrial thrombus by TEE does not preclude thromboembolism in the 
absence of therapeutic anticoagulation. Black et al. [150], reported 17 patients with 
nonvalvular AF who had embolic events 2 hours to 7 days after cardioversion despite a TEE 
showing no LA thrombus. None of the patients were on therapeutic anticoagulation at time 
of embolism. Thus, the TEE-guided cardioversion strategy should be coupled with 
therapeutic anticoagulation at the time of and after cardioversion for patients whose AF is 
greater than 48 hours in duration.
It is recognized that in the thoracic surgery population, some patients will not be candidates 
for TEE because of esophageal procedures, including esophagectomy (or those with 
esophageal pathology). In these patients, if AF duration is > 48 hrs, an initial rate control 
approach is reasonable with therapeutic anticoagulation, using warfarin (INR 2.0 to 3.0), a 
direct thrombin inhibitor (e.g. dabigatran), factor Xa inhibitor (e.g. rivaroxaban, apixaban), 
or LMWH, recommended for at least 3 weeks prior to and 4 weeks after cardioversion. 
Cardiac CT has been used to assess for LAA thrombus, predominantly prior to AF catheter 
ablation. A recent meta-analysis [151] reported accuracy comparable to TEE, especially 
when delayed images were acquired, with a sensitivity and specificity of 96% and 92% 
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compared to TEE, a positive predictive value of 41% and negative predictive value of 99%. 
As clinical outcomes studies are needed to assess its clinical utility for cardioversion, in the 
case of patients with esophageal surgical procedures precluding TEE, the rate control 
strategy with deferred cardioversion until at least 3 weeks of therapeutic anticoagulation is 
achieved seems reasonable. For selected patients, a cardiac CT may be of some value.
RECOMMENDATION
5.7. Recommendation for EP catheter ablation
Class III
5.7.1. Catheter or surgical ablation of AF is not recommended for management of 
patients with postoperative AF after thoracic surgery. (LOE C).
REASONING—Catheter ablation of AF is a well-established and commonly employed 
therapeutic option for managing patients with symptomatic AF [2], [3]. At the present time, 
catheter ablation of AF plays no role in the management of patients who develop AF in the 
early post-operative setting. This recommendation is based on a number of important 
considerations. First, all patients who undergo catheter ablation of AF must be 
anticoagulated for a minimum of two months following ablation. Patients who cannot be 
anticoagulated continuously for two months are not considered to be ablation candidates. 
Second, catheter ablation of AF is a complex and lengthy procedure (3 to 6 hours) that is 
most commonly performed under general anesthesia. Third, it is very common for AF to 
recur in the 2 – 3 month post ablation “healing phase.” This reflects the presence of 
considerable inflammation and lesion maturation that occurs post ablation. The presence of 
these “healing phase” arrhythmias means that AF ablation is an inappropriate strategy for 
control of acute, symptomatic AF, such as occurs in the postoperative setting. Fourth, the 
efficacy of catheter ablation is modest. In optimal candidates for the procedure with 
paroxysmal AF who are otherwise healthy the single procedure success rate at 12 months is 
60% to 80%. Late recurrences following 12 months of follow-up are common. And finally, 
AF ablation is associated with a significant risk of complications. For more information 
regarding the technique, risks, indications, and outcomes of AF ablation, please refer to the 
2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of 
Atrial Fibrillation [152].
RECOMMENDATIONS
5.8. Surgical and interventional treatment options
5.8.1. Recommendations for Pre-Existing AF
5.8.1.1. Pre-existing AF should be managed according to existing guidelines for non-
postoperative AF (see section 6).
REASONING—Pre-existing AF should be treated according to the existing guidelines for 
non-surgical AF [2], [3]. In the rare situation where a patient cannot be treated with 
anticoagulation, consideration could be given to intra operative left atrial appendage 
resection or ligation. This could only be done if the patient is undergoing a left thoracotomy 
procedure. Regarding pulmonary vein isolation procedures, a complete bilateral procedure 
Frendl et al. Page 32













can only be performed in the rare situation when bilateral thoracotomies are performed or if 
a clam-shell incision is employed.
New onset AF following thoracic surgery: An intraoperative procedure is not indicated 
based solely on a prediction model for patients likely to develop POAF. Procedures such as 
pulmonary vein isolation (PVI) and/or left atrial appendage resection or ligation are not 
routinely practiced for prevention of POAF in cardiac surgery, where the exposure allows 
such procedures to be performed easily.
New onset AF following thoracic surgery: long term strategies: It is well known that the 
overwhelming majority of POAF is self-limiting to 4–6 weeks. For persistent AF beyond 
that time or POAF requiring long term anticoagulation, patients should be referred to a 
cardiologist/cardiac electrophysiologist for future management according to general AF 
guidelines. If such patients are intolerant of antiarrhythmic medications, a catheter-based 
ablation procedure may be offered according to the existing guidelines for AF ablation. A 
surgical ablation procedure can be offered in the rare instance of a patient requiring a cardiac 
surgical procedure. A full PVI or LA maze and possible RA maze procedure may be 
performed. In addition, a left atrial appendage exclusion procedure could be also performed. 
If such patients are intolerant of long-term anticoagulation, left atrial appendage exclusion 
could be considered [127], [153].
6. Management of the patient with pre-existing AF (figure 7)
Patients with preexisting AF represent a high-risk population for stroke, heart failure and 
other POAF related complications. Some may have valvular heart disease. The management 
of their antiarrhythmic medications, and their perioperative anticoagulation may pose a 
challenge.
RECOMMENDATIONS
6.1. Criteria for obtaining cardiology consult for pre-operative AF
Class IIa
6.1.1. Pre-operative cardiology consult can be useful for patients with pre-operative AF 
that is either newly diagnosed or persistent and symptomatic. (LOE C)
6.2. Perioperative management of anticoagulation for patients on long-term 
(warfarin or NOAC) anticoagulation
Class I
6.2.1. Decisions regarding the duration of interruption of anticoagulation and/or the 
need for perioperative heparin bridging should be based on the patient’s stroke risk 
profile (based on their CHA2DS2-VASc score). (LOE C)
Class IIa
6.2.2. For patients who have a high stroke risk (based on their CHA2DS2-VASc score 
(figure 9 and 10), history of prior stroke, or presence of a mechanical heart valve, 
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perioperative bridging with a short-acting anticoagulant (i.e. enoxaparin) is reasonable 
for patients with eGFR>50% when warfarin anticoagulation is withheld. (LOE C)
Class IIb
6.2.3. Short-term withdrawal of anticoagulation without bridging may be considered for 
those patients who are on anticoagulation preoperatively as part of their treatment for 
persistent AF but have a CHA2DS2-VASc score less than 2, have not had heart failure, 
have an EF above 35%, and/or for whom bridging anticoagulation would be 
burdensome or otherwise undesirable. (LOE C)
6.3. Post-operative resumption of anti-coagulation
Class IIa
6.3.1. If anticoagulation is interrupted, the duration should be minimized. It is 
reasonable to base decisions about the duration of interruption and the time of 
resumption of anticoagulation on the patient’s stroke risk profile (CHA2DS2-VASc 
score) weighed against the risk of postoperative bleeding. (LOE C)
6.4. Post-operative follow-up
Class IIb
6.4.1. It is reasonable to consider postoperative follow-up with a cardiology specialist 
for patients with preoperatively identified AF who meet one or more of the following 
criteria:
6.4.1.1. Ejection fraction ≤ 45% or diagnosis of systolic heart failure or 
cardiomyopathy;
6.4.1.2. Discharged on a new rate control and/or rhythm control agent(s);
6.4.1.3. Dose of a home rhythm control agent(s) was adjusted while inpatient;
6.4.1.4. Discharged on a new anticoagulant (parenteral and/or oral). (LOE C)
REASONING—In the Rocket AF trial comparing warfarin and rivaroxaban for the 
prevention of thromboembolism in non-valvular AF, 33% of the 14,236 patients had a 
temporary interruption of anticoagulation of greater than or equal to 3 days (mean duration 5 
days). 81% of these patients had persistent AF and greater than 99% had a CHADS2 score 
greater than or equal to 2 (mean 3.4) [154]. 50% of the patients had a history of stroke or 
TIA and 62% had a history of CHF. 40% of the temporary interruptions were for 
procedures, though only 14% were for abdominal, thoracic, orthopedic, or cardiac 
procedures. The 30 day stroke or systemic embolism rate of 0.36%, though similar in both 
the rivaroxiban and warfarin groups, 0.30% vs. 0.41% (HR 0.74 C.I. 0.36–1.5 p=0.4) was 
higher than the overall 2.2%/year rate throughout the study.
In the Rocket AF study [154], bridging of anticoagulation for temporary interruptions was 
tracked, and only 6% of the temporary interruptions were bridged, 98.6% with low 
molecular weight heparin (LMWH) and 1.4% with fondaparinux. The bridge group was 
slightly older, 74 vs 73 years (p 0.019), had a fractionally higher CHADS2 score, 3.52 vs 
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3.40 (p 0.0094), more often had diabetes, 48 vs 41% (p 0.0049), and had more temporary 
interruptions. The bridge group prior stroke and TIA as well as CHF rates were similar to 
the non-bridge group. The bridged patients had only 1 stroke/embolic event, a 30 day rate of 
0.17%, whereas the non bridge group 30 day event rate was 0.37%. Major bleeding was 
similar in both groups, but the bridged group had a higher incidence of major/non major 
clinically relevant bleeding, 4.83% vs. 3.02%. Due to small numbers and variable reasons 
for bridging, statistical significance was not calculated. These data raise the concern that 
discontinuation of anticoagulation may expose the patients to a small but significant risk of 
stroke.
Additional data that suggest the importance of considering the risk of stroke when 
contemplating the temporary interruption of anticoagulation was derived from data obtained 
after the closing of the Rocket AF trial. Following cessation of study medication, the 
rivaroxiban patients required an average of 13 days to achieve a therapeutic INR, while the 
patients receiving warfarin required only 3 days. The rivaroxiban group had 22 embolic 
events while the warfarin group had 7 events over 31 days of follow-up [155]. The full role 
of perioperative bridging will be further elucidated in two ongoing randomized trials, 
BRIDGE (Effectiveness of bridging anticoagulation for surgery [http://trials.gov]) and 
PERIOP-2 (a double blind randomized controlled trial of post operative low molecular 
weight heparin bridging therapy vs. placebo bridging therapy for patients who are at high 
risk for arterio-thromboembolism [http://trials.gov]).
7. Management of anticoagulation for new onset POAF
In order to minimize the risk of perioperative bleeding while providing sufficient protection 
from the POAF-related strokes a careful evaluation of the patients’ stroke risk is essential. 
The recently approved novel oral anticoagulants (NOAC; direct thrombin inhibitors and 
anti-Factor Xa agents) offer alternatives to warfarin, and are gaining popularity in the 
community for the long-term management of AF-related anticoagulation.
RECOMMENDATIONS
Class I
7.1. For the prevention of strokes for patients who develop POAF lasting longer than 48 
hours, it is recommended to administer antithrombotic medications similarly to non-
surgical patients (figure 8). Decision to initiate therapy should be based upon the benefit 
of reducing stroke risk versus the risk of bleeding in the post-operative period [15], 
[17], [42], [45], [95], [97], [116], [118], [119], [156]–[158]. (LOE A)
7.1.1. For effective anticoagulation, an INR range of 2–3, with a target of 2.5, for 
warfarin is recommended unless otherwise contraindicated [120]–[122], [159], [160]. 
(LOE A)
7.1.2. The INR should be determined at least weekly during initiation of therapy and 
monthly when the doses of anticoagulant and the INR are stable [123], [161]–[163]. 
(LOE A)
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REASONING—The overall risk of a perioperative stroke in all patients undergoing 
anesthesia has been estimated at 0.5–0.8% in large studies of patients who have had non-
cardiac surgery [164], [165]. One of these studies use the Nationwide Inpatient Sample of 
131,067 patients and determined that among 39,339 patients undergoing pulmonary 
lobectomy/segmentectomy the incidence of acute ischemic stroke was 0.6% which rose to 
0.8% for patients over 65 yr., respectively [164]. Risk factors associated with perioperative 
stroke in that study were renal disease, atrial fibrillation, history of stroke and cardiac 
valvular disease [164]. Mortality in patients who developed a stroke after lung resection was 
33% compared to 3.2% in those who did not [164]. The reported incidence of stroke or 
transient neurological injury of 1.6–3.3% after cardiac operations is consistently greater for 
patients who develop persistent postoperative AF compared to 0.2–1.4% for those without 
AF [166]. It has been established that oral anticoagulation with warfarin is associated with 
60–70% reduction from the 4–5% overall risk of ischemic stroke per year in patients with 
persistent or chronic non-valvular AF not receiving warfarin [45], [157], [158], [167]. 
Depending of the type of surgery (total hip replacement, hemicolectomy or lung resection), 
12–33% of arterial thromboembolic events are fatal and more than 40% result in serious 
permanent disability [156], [158]. On the other hand, 3% of episodes of major postoperative 
bleeding are fatal but most patients make a full recovery. As many as 50% of bleeding 
episodes require a re-operation [156]. A retrospective study of patients who developed new 
onset AF after general thoracic surgery compared patients that received some form of 
antithrombotic therapy for AF to those who did not receive anticoagulation and found that 
patients who were anticoagulated had stroke rate of 2.2% compared to 0.6%, respectively as 
well as had a greater incidence of bleeding episodes [167]. In that study patients who were 
anticoagulated had more comorbidities and greater risk score for stroke. Whether individuals 
require short-term anticoagulation must be individualized for each patient based on the 
intrinsic risk for thromboembolism and risk of bleeding [45], [157], [158]. For most types of 
surgery initiation or resumption of warfarin can be undertaken 12–24 hours after surgery 
unless the patient is at special risk for bleeding such as those with a low platelet count, 
prolonged excessive chest drainage or those who might require an invasive procedure within 
days or weeks of discharge such developing an anastomotic leak after esophagectomy, for 
example [45], [156]–[158], [167]. These latter patients may better be managed by LMWH 
and/or by a TEE-guided “fast-track” strategy to rule out a left atrial appendage thrombus and 
then receive DC cardioversion [157], [158], [166]. Since the potential for thromboembolism 
with new onset AF develops early, prompt attempts to restore sinus rhythm within this 
period should be made. If the arrhythmia persists beyond 24–48 hrs anticoagulant therapy 
should be considered after weighing the risk of postoperative bleeding. In a prospective 
study of 330 patients undergoing anatomic lung resection, 1 of 60 patients (1.7%) with 
postoperative AF developed a stroke within 24 h of AF onset and Holter monitoring later 
showed that the initial 12 h of AF were asymptomatic [27]. Others have questioned the 48 h 
window and suggest that it might be reasonable to start anticoagulation therapy in the first 
48 h if multiple risk factors for stroke are present. They further suggest that a TEE-guided 
strategy may prove useful in situations where both the risk of stroke and risk of 
postoperative bleeding pose a dilemma regardless of the fact that AF was not present for 48 
h [168].
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The goal of anticoagulation should balance the risk of stroke and the risk of bleeding. The 
range should be optimal for adequate stroke prevention but at the same time should be at the 
minimal bleeding threshold. In AF, INR range of 2.0–3.0 with target of 2.5 should fulfill this 
requirement [169]. Randomized control studies have shown that warfarin therapy with an 
INR 2.0–3.0 was associated with improved outcome compared to aspirin [170]. Hylek et al. 
retrospectively studied 13559 patients with non-valvular AF and showed that INR<2 at 
admission was associated with an increased number of strokes [159]. Recently, in the RE-
LY trial, a randomized controlled trial which compared the outcomes of warfarin vs 
dabigatran treatment in AF patients. Warfarin was managed with the target INR was 2.0 to 
3.0 and the maximum interval between INR tests was 4 weeks. They used an algorithm to 
manage the INR, e.g. +15% dose/week increase for INR<1.5, +10% dose/week increase for 
INR 1.5–1.99, −10% dose/week decrease for INR 3.01–4.00. Instillation of this algorithm 
resulted an increase in TTR [160].
For in-hospital patients on warfarin, INR is measured every day until it is therapeutic. For 
outpatient follow-up, INR is followed every few days until it reaches the stable therapeutic 
target, then the interval can be prolonged as long as 4–6weeks. The frequency of follow up 
depends on patients’ compliance, drug and food interactions, interruption for surgical 
procedures and existence of other comorbidities [161]. Its frequency should be increased 
when switching over to another type of anticoagulant, such as heparin-bridge. Pengo et al. 
randomized 124 patients to 4-week interval and 6-week interval follow-up of INR testing for 
patients with prosthetic mechanical valves and showed that there was no difference in their 
time in therapeutic range (TTR) [162]. Schulman et al. showed in their randomized study of 
250 patients receiving warfarin, followed at 4-week intervals versus 12-week intervals with 
phone follow up every 4 weeks that the 12-week interval group had similar TTR and 
bleeding/embolic events [163]. The American College of Chest Physicians recommends 
follow up interval of up to 12 weeks if INR is stable [161].
RECOMMENDATIONS
Class I
7.2. Anticoagulation within the first 48-hrs of POAF (figure 9) should be considered 
based on the CHA2DS2-VASc risk score (figure 10) of the patient for stroke weighed 
against the risk of postoperative bleeding. (LOE C)
7.2.1. For risk assessment, the following may serve as a guide: CHA2DS2-VASc risk 
score (figure 10) for stroke [2]–[4], [147]. (LOE A):
S=0: no anticoagulation recommended
S=1: anticoagulation should be considered if its benefits outweigh the risk of 
bleeding
S=2 anticoagulation is highly recommended if its benefits outweigh the risk of 
bleeding
7.2.2. The presence of impaired renal function should weigh in favor of 
anticoagulation. Caution should be exercised when patients on dialysis are considered 
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for anticoagulation as the benefits for those patients are less certain [2], [3], [171]–
[174]. (LOE A)
7.2.3. If not precluded by concerns for bleeding, anticoagulation is also recommended 
when conversion to sinus rhythm is attempted by (DC or chemical) cardioversion (as 
above) [2], [3], [45], [157], [158]. (LOE C)
REASONING—Since the analysis by the Atrial Fibrillation Investigators (AFI) of the first 
5 prospective, randomized, clinical trials comparing oral anticoagulants with placebo and 
sometimes with aspirin, we have learned that not all patients with atrial fibrillation have the 
same risk of stroke [175], [176]. The AFI demonstrated that stroke risk may be stratified by 
several factors, including a prior thromboembolic event or transient ischemic attack, 
hypertension, diabetes, congestive heart failure, poor left ventricular function, and age 65 
years of age or older. Stroke risk was further stratified to mild, moderate and severe 
categories. Other risks such as coronary artery disease, peripheral vascular disease, gender, 
thyrotoxicosis, rheumatic mitral valve disease, and hypertrophic cardiomyopathy were also 
important risk markers to consider.
To translate these risks derived from group data to the individual, there are now several 
stroke risk stratification schemes available. Initially, most guidelines adopted the CHADS2 
stroke risk stratification scheme, and it has been widely used for many years [2], [3]. 
Recently the CHA2DS2-VASc stroke risk stratification scheme (figure 10) has taken 
prominence, having being adopted by the European Society of Cardiology, and the 
American College of Cardiology Foundation/American Heart Association/Heart Rhythm 
Society guidelines [2], [3], [147]. A major reason for its use is that it is better at sorting out 
those patients with low stroke risks who really don’t need anticoagulation for prophylaxis, 
and those who do. Thus, a CHADS2 score of 0 or 1 is associated with an annual risk of 1.9% 
to 2.8%, respectively, not really small risks at all. However, when applying the CHA2DS2-
VASc stroke risk scheme to those same patients, the CHA2DS2-VASc score is anywhere 
from 0 to 4. A CHA2DS2-VASc of 3 or 4 carries an indication for use of anticoagulation 
therapy, whereas a CHA2DS2-VASc score of 0 does not. A CHA2DS2-VASc score of 1 
carries the recommendation to consider the use of anticoagulation therapy.
The recommendations using the CHA2DS2-VASc score are that if CHA2DS2-VASc score is 
0, the patient does not require anticoagulation. For a CHA2DS2-VASc score of 1, oral 
anticoagulation could be considered, while for a CHA2DS2-VASc of 2 or more, oral 
anticoagulation is generally indicated [147]. Although the recently published 
ACCF/AHA/HRS AF guidelines suggested that for a CHADS-VASC score of 1, it is 
reasonable to consider to use no antithrombotic therapy or aspirin if the burden of 
cardiovascular disease is otherwise low [2], [3]. However, the vast majority of thoracic 
surgical patients who develop (or have) AF would likely have an indication for 
anticoagulation using the CHA2DS2-VASc risk scoring system. Because of its ease of use, 
and its wide acceptance, the use of the CHA2DS2-VASc score is recommended for the 
assessment of stroke risk.
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Several scoring systems have been reported to identify the risk of bleeding following the 
initiation of anticoagulation [171]–[173]. These scoring systems are not recommended for 
routine use as standard practice. However, among the risk factors, end-stage renal disease on 
hemodialysis is considered to pose a significant risk for bleeding when these patients are 
anticoagulated. Recently published retrospective review of 1626 dialyzed patients and non-
dialyzed patients, anticoagulation for dialyzed patients did not decrease the risk of stroke, 
but increased the incidence of bleeding episodes with 44% [174].
RECOMMENDATIONS
Class IIa
7.3. New oral anticoagulants (Dabigatran, Rivaroxiban, Apixiban; [177]–[180]) are 
reasonable as an alternative to warfarin (table 8) for patients who do not have a 
prosthetic heart valve, hemodynamically significant valve disease, and/or severe renal 
impairment or risk of GI bleeding [2], [26], [106], [128]–[130], [155]. (LOE B)
7.4. It is reasonable to continue anticoagulation therapy for 4 weeks after the return of 
sinus rhythm because of the possibility of slowly resolving impairment of atrial 
contraction with an associated ongoing risk for thrombus formation and for delayed 
embolic events [45], [157], [158]. (LOE C)
REASONING—Newer oral anticoagulant drugs have recently become available, including 
dabigatran, rivaroxaban, and apixaban. Dabigatran is an oral direct thrombin inhibitor, while 
rivaroxaban and apixaban are factor Xa inhibitors. Compared with warfarin, these agents 
offer the advantage of not requiring monitoring of the International Normalized Ratio (INR). 
The efficacy of dabigatran for stroke prevention in nonsurgical, nonvalvular AF was 
compared with that of warfarin in the Randomized Evaluation of Long-Term 
Anticoagulation therapy (RE-LY) trial [181], which was a prospective noninferiority study 
that randomized 18,113 patients into three groups: dabigatran 110 mg twice daily or 
dabigatran 150 mg twice daily, administered in blinded fashion, or warfarin titrated to an 
INR of 2.0–3.0, administered in unblinded fashion for a median duration of 2 years. 
Dabigatran 150 mg twice daily significantly reduced the risk of stroke or systemic embolism 
by 34% compared to warfarin. There was no significant difference in the incidence of death 
in either dabigatran group compared with that in warfarin-treated patients. There was no 
difference between the warfarin and dabigatran 150 mg twice-daily groups in incidence of 
major bleeding. However, dabigatran 150 mg twice daily was associated with a significantly 
lower incidence of hemorrhagic stroke compared with that in the warfarin group. The 
efficacy of rivaroxaban for reducing risk of stroke in patients with nonsurgical, non-valvular 
AF was compared with that of warfarin in the Rivaroxaban Once Daily Oral direct Factor 
Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and 
Embolism in Atrial Fibrillation (ROCKET-AF) trial [155]. In this non-inferiority study, 
14,264 patients with AF were randomized in double-blind fashion to receive rivaroxaban 20 
mg orally daily or warfarin, titrated to an INR of 2.0–3.0 for a median treatment period of 
590 days (median follow-up 707 days). Compared with warfarin, rivaroxaban significantly 
reduced the risk of stroke or systemic embolism by 21%. Using an intention-to-treat 
analysis, there was no significant difference between rivaroxaban and warfarin in the 
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incidence of stroke or systemic embolism. There was no difference between the groups in 
the incidence of major and non-major clinically relevant bleeding. However, the incidence 
of intracranial hemorrhage and fatal bleeding was significantly lower in rivaroxaban-treated 
patients. The efficacy of apixaban compared to that of warfarin for stroke prevention in 
nonsurgical, non-valvular AF was investigated in the Apixaban for Prevention of Stroke in 
Subjects with Atrial Fibrillation (ARISTOTLE) non-inferiority trial [182]. Patients 
(n=18,201) with AF and at least one additional risk factor for stroke were randomized to 
receive apixaban 5 mg orally twice daily or warfarin, titrated to an INR of 2.0–3.0 for a 
median duration of follow-up of 1.8 years. The risk of ischemic or hemorrhagic stroke or 
systemic embolism in the apixaban group was significantly lower than in the warfarin group, 
as was the incidence of death from any cause. The incidences of major bleeding and 
hemorrhagic stroke were also significantly lower in apixaban-treated patients. There was no 
difference between the groups in the incidence of ischemic or uncertain type of stroke.
Patients who received standard anticoagulation upon discharge from the hospital can return 
for cardioversion between 3 – 12 weeks after initiation of anticoagulant therapy [45], [156], 
[166]. Patient who convert to sinus rhythm but are experiencing intermittent paroxysms of 
AF may be considered for anticoagulation for 1 month after the return of sinus rhythm since 
it has been shown that impaired atrial mechanical function can persist for several weeks 
after return of sinus rhythm [45], [157].
RECOMMENDATIONS
Class III
7.5. New oral anticoagulants should be avoided for patients at risk for serious bleeding 
(including gastrointestinal bleeding) as they cannot be readily reversed. However, their 
use may be recommended in situations where achievement of a therapeutic INR with 
warfarin has proved to be difficult [2], [128], [130], [183]. (LOE C)
REASONING—A large phase II randomized control study, namely RE-ALIGN trial which 
studied patients who underwent implantation of mechanical valve (aortic or mitral) or have 
undergone implantation of mitral bileaflet valve < 3 months before randomization [183]. 
The trial was terminated due to increase in strokes (5% vs 0%), myocardial infarction (MI) 
and major bleeding (4% vs 2%) in dabigatran group. Currently, dabigatran is contraindicated 
and should not be used in patients with mechanical valves.
8. Recommendations for long-term management and follow-up of patients with persistent 
new onset POAF (figure 11)
Those patients with POAF-related perioperative complications, and those requiring long-
term management of antiarrhythmics and anticoagulants are likely to benefit from 
cardiology follow-up after their discharge.
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8.1. Post-discharge follow-up and management recommendations for 
persistent new onset POAF
Class I
8.1.1. For patients who have a complicated in-hospital course related to their POAF, 
who have underlying structural heart disease, or who experience sequelae of AF, such 
as MI or decreased LVEF, follow-up with cardiology should be arranged at the time of 
discharge. (LOE C)
Class IIb
8.1.2. Patients with well-controlled new onset POAF (either converted to sinus rhythm 
or with good rate control) may be seen in routine follow up by the surgical team without 
cardiology follow up. (LOE C)
REASONING—The majority of cases of POAF are self-limited and even when present at 
discharge, will have resolved by the time of follow-up. There is little literature regarding 
post-discharge risks for general thoracic patients specifically. Recommendations regarding 
cardiology follow up for complicated patients seem self-evident. The appropriate timing for 
cardiology follow up should be individualized prior to discharge. For uncomplicated patients 
there is some evidence for guidance. Following lung resection, Rena et al. demonstrated that 
98% of POAF resolved after discharge, although as an older study, 80% were given 
digitalis. The duration was between 1 and 12 days, with an average of 2 days [106]. It has 
been estimated that approximately 50% of episodes of POAF spontaneously convert to 
normal sinus rhythm within 12 hours [184]. Given the relatively short duration of POAF in 
most cases, it is unclear when the first postoperative visit to the surgeon in uncomplicated 
cases should be. The 2010 guidelines of the Canadian Cardiovascular Society recommend 
that medical management of AF and anti-coagulation should be reassessed at 6–12 weeks 
postoperatively, although this primarily was intended for cardiac surgical patients. This was 
considered a strong recommendation, with moderate evidence but no reference was given 
[185]. Kowey reported a retrospective analysis of 116 patients with POAF following 
coronary bypass surgery. There were 36 patients treated with antiarrhythmic and rate control 
drugs compared to 76 treated with rate control agents alone. Only 1 patient in each group 
was still in AF at 6-week follow-up [186]). In another study following coronary bypass 
surgery, Izhar et al. randomized 129 patients who had converted to sinus rhythm before 
discharge to 1, 3, or 6 weeks of antiarrhythmic therapy. There was no difference in the rate 
of recurrent AF with 0, 2, and 0 patients in the three groups. The majority of the patients 
were managed with amiodarone [187]. On this basis, it seems reasonable that the timing of 
routine surgical follow up should be dictated by surgical considerations, and the presence or 
absence of AF assessed at that time.
Despite the relatively self-limited nature of the vast majority of cases of POAF, the long-
term significance of a single episode of POAF is unknown [188]. Ahlsson has studied the 
late outcome of patients who developed POAF after coronary bypass surgery and found that 
the development of AF was a risk factor for late mortality. Whether this applies to patients 
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after non-cardiac thoracic surgery is unknown. However, it seems prudent to ensure 
communication with the primary care physician for vigilant follow up of cardiovascular and 
AF risk factors.
RECOMMENDATIONS
8.2. Management of anti-arrhythmic medications
Class IIa
8.2.1. For patients who have converted to sinus rhythm prior to hospital discharge, it is 
reasonable to consider discontinuation of anti-arrhythmic medications 4 weeks after the 
ECG documented return of normal sinus rhythm or at the first post-operative visit 
(usually 2–6 weeks after discharge). (LOE C)
Class IIb
8.2.2. For patients with new onset POAF who were discharged in AF but who are in 
normal sinus rhythm (ECG confirmed) at the first post-operative visit, it may be 
reasonable to instruct the patients to self discontinue the anti-arrhythmic medications 4 
weeks following the visit if no signs of AF recur. (LOE C)
REASONING—There is no clear evidence to guide duration of anti-arrhythmic therapy 
following non-cardiac thoracic surgery. Landymore et al. followed 58 patients following 
coronary artery bypass grafting with ambulatory Holter monitoring, including 3 patients 
who developed spontaneous symptomatic AF and received digitalis for rate control. Sixteen 
patients (group 2) continued taking digoxin for 8 weeks following operation, 13 patients 
(group 3) discontinued digoxin treatment 5 weeks following operation, and 14 patients 
(group 4) discontinued digoxin treatment 3 weeks following operation. Twenty-four hour 
Holter monitoring indicated that asymptomatic AF was common in the treatment groups 
after digitalization just before discharge from hospital. Recurrence of AF was rare following 
discharge [189]. Yilmaz performed a similar smaller study, with 120 patients who had 
converted to sinus rhythm (pharmacologically or with DCC) enrolled to a prospective 
randomized trial of placebo or 1 of three drugs (amiodarone, verapamil, or quinidine) post 
discharge. Patients underwent 24-hour Holter monitoring 6 times over 9 months 
postoperatively. Recurrent AF usually developed within 15 days of discharge. AF occurred 
in only one patient (3.33%) in group 1, and two each (6.66%) in each of the drug groups 
[190].
RECOMMENDATIONS
8.3. Management of anticoagulation
Class I
8.3.1. For patients who are started on anticoagulants, the anticoagulation should 
continue for a minimum of 4 weeks after return to NSR is documented. (LOE C)
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8.3.2. More prolonged anticoagulation (longer than 4 weeks after return to NSR) can be 
beneficial in the presence of stroke risk factors (CHA2DS2-VASc score) or if the patient 
had a prior stroke. The concomitant presence of mild or moderately impaired kidney 
function weighs in favor of a longer period of anticoagulation. (LOE B)
8.4. Recommendations for long-term management of new onset, persistent 
POAF
Class IIa
8.4.1. Patients with new onset POAF persisting for or recurring after 4–6 weeks (or at 
the time of the first post-operative visit) can benefit from referral to a cardiologist for 
long-term management of stroke risk as well as anti-arrhythmic or anticoagulant 
medications.. (LOE C)
REASONING—The ideal duration of anti-coagulation following POAF is unknown. 
European guidelines have concluded that there is insufficient evidence to make any 
recommendation [191]. Others have concluded that it is reasonable to continue anti-
coagulation for 4 weeks, on the basis that atrial contraction is impaired long after the AF has 
ceased [4]. All the current evidence in this area is Level C.
Recommendations for future AATS efforts: The taskforce recommends the establishment 
of a high fidelity thoracic surgery database, that uses the uniform definitions and monitoring 
strategies recommended here, stratifies by surgery type, and systematically documents the 
occurrence, duration, and complications of POAF and its treatment. The aim would be to 
develop risk prediction models, and eventually randomized interventional trials, for the 
prevention and treatment of POAF, specific to thoracic surgery. This could be most readily 
accomplished by enriching the STS data collections system.
Recommendations for the use of the guidelines: These guidelines are best used as a guide 
for practice and teaching. The applicability of these recommendations to the individual 
patient should be evaluated on a case-by-case basis, and only applied when clinically 
appropriate. Additionally, these guidelines can serve as a tool for uniform practices, to guide 
preoperative evaluations, and form the basis of large, multicenter cohort studies for the 
thoracic surgical community.
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Prevention Strategies and Their Efficacy for Postoperative Atrial Fibrillation (POAF)
Abbreviations: PVI: pulmonary vein isolation; LVEF: left ventricular ejection fraction; AF: 
atrial fibrillation
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Management Algorithm for Postoperative Atrial Fibrillation (POAF)
Abbreviations: AF: atrial fibrillation; MI: myocardial infarction; HF: heart failure; WPW: 
Wolf-Parkinson-White syndrome
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Management of the Hemodynamically Unstable Patient with New Onset Postoperative 
Atrial Fibrillation (POAF)
Abbreviations: AF: atrial fibrillation; HF: heart failure; DC cardioversion: direct current 
cardioversion; i.v.: intravenous
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Management of the Hemodynamically Stable Patient with New Onset POAF of Less than 
48Hrs of Duration
Abbreviations: AF: atrial fibrillation; WPW: Wolf-Parkinson-White syndrome; ; i.v.: 
intravenous; HF: heart failure; DC cardioversion: direct current cardioversion
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Management of the Hemodynamically Stable Patient with New Onset Postoperative Atrial 
Fibrillation (POAF) of More than 48Hrs of Duration
Abbreviations: AF: atrial fibrillation; WPW: Wolf-Parkinson-White syndrome; ; i.v.: 
intravenous; HF: heart failure; DC cardioversion: direct current cardioversion; TEE: 
transesophageal echocardiogram; LA/LAA: left atrial / left atrial appendage
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a: Antiarrhythmic Drugs Recommended for Pharmacologic Cardioversion of Postoperative 
Atrial Fibrillation (POAF)
Abbreviations: MI: myocardial infarction; CAD: coronary artery disease, LV: left 
vertricular; CHF: congestive heart failure; AV: atrio-ventricular
b: Antiarrhythmic Drugs Recommended for Maintenance of Sinus Rhythm after 
Cardioversion of Postoperative Atrial Fibrillation (POAF)
Abbreviations: CAD: coronary artery disease; HF: heart failure; MI: myocardial infarction; 
CAD: coronary artery disease, LV: left vertricular; AV: atrio-ventricular
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Algorithm for the Management of Patients with Preoperative Atrial Fibrillation (AF)
Abbreviations: CHF: congestive heart failure; SOB: shortness of breath; CoR: Class of 
Recommendation; LOE: Level of Evidence; CHA2DS2-VASc: CHA2DS2-VASc score
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Management of Anticoagulation for Postoperative Atrial Fibrillation (POAF) Lasting 
Longer than 48Hrs
Abbreviations: INR: international normalized ratio, NOAC: new oral anticoagulants
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Considerations for the Management of Anticoagulation within the First 48hrs of 
Postoperative Atrial Fibrillation (POAF)
Abbreviations: CHA2DS2-VASc: CHA2DS2-VASc score
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Stroke Risk Stratification in Atrial Fibrillation
Abbreviations: CHA2DS2-VASc: CHA2DS2-VASc score, HTN: hypertension; MI: 
myocardial infarction; PAD: peripheral arterial disease
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Recommendation for the Post-Discharge Follow-Up for Patient with New Onset 
Postoperative Atrial Fibrillation (POAF)
Abbreviations: NSR: normal sinus rhythm; EF: ejection fraction
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Table 1
Size of Treatment Effect and Level of Evidence for Its Impact
Schema used to guide the grading of available published evidence and the expected effect of the interventions for their impact on patient outcomes 
(the arrow indicates the direction of increased effects size).
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Table 2
a: Risk Stratification of Thoracic Surgical Procedures for Their Risk of Postoperative Atrial Fibrillation 
(POAF)
Thoracic surgical procedures were divided into low (<5%), moderate (5–15%) and high (>15%) risk groups 
based on their expected incidence of POAF (references in parenthesis) in order to facilitate the preoperative 
risk stratification of patients.
b: Known Patient Risk Factors for and Comorbidities which Increase the Risk of Postoperative Atrial 
Fibrillation (POAF)
Patient risk factors and comorbidities which were shown to increase the risk of atrial fibrillation (AF) are 
listed. Much of this information was extracted from the general population, thoracic surgery specific 
references are listed when available. These risk factors/comorbidities should be assessed in conjunction with 
the procedure-related risks of AF in order to determine the true risk of POAF.









  Minor Procedures
• Flexible 
Bronchoscopy 





• Placement of 
thoracostomy 

















  Major Procedures • Segmentectomy (5, 6)





• Open Thoracotomy 
for Lobectomy (5–
11)
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• Laparoscopic Nissen 
Fundoplication/Myotomy
• Zenker’s Diverticulectomy
• Esophagectomy (5, 
8, 17)
Other Procedures • Pericardial Window
Risk Factors and Co-Morbidities Thoracic Surgery References
Modifiable Risk Factors
Hypertension 8, 10, 18
MI 19
VHD










Increased LV wall thickness
Non-Modifiable Risk Factors
Increasing age 5–6, 8, 10, 19–20
African-American (protective factor) 10
Family history
Genetic variants
Male Sex 5, 8, 10, 20
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Risk Factors and Co-Morbidities Thoracic Surgery References
h/o Arrythmias 5–6
References in parentheses
Derived from 2014 AHA AF Guidelines and relevant literature for thoracic surgery.
Abbreviations: MI: myocardial infarction; VHD: ; LV: left ventricle; LVH: left ventricular hypertrophy; h/o: history.
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Table 3
Probable Mechanisms Contributing to Postoperative Atrial Fibrillation (POAF)
■ Clinically meaningful AF requires the presence of both a trigger and a vulnerable atrial substrate
■ Atrial substrate changes that facilitate AF
➢ Sympathetic or parasympathetic stimulation
➢ Atrial dilation or acute atrial stretch
➢ Pericarditis
➢ Fibrosis
➢ Inhomogeneous dispersion of conduction abnormalities
➢ Short wavelength (conduction velocity × ERP)
➢ Other (like Inflammation and oxidative stress)
■ In addition, a driver(s) is thought to be needed to sustain AF in the vulnerable substrate
➢ Rapidly firing ectopic focus (atrial or other)
➢ Reentrant circuit(s) of short cycle length (ordered reentry)
➢ Potential role, if any, of multiple reentrant wavelets (random reentry)
Abbreviations: AF: atrial fibrillation; ERP:.













Frendl et al. Page 75
Table 4
Recommended Definitions for the Diagnosis of Postoperative Atrial Fibrillation (POAF)
Definitions COR
Electro-physiologic definition/diagnosis ECG recordings (one or more ECG leads) with ECG features of AF lasting at least for 30 seconds or for the duration of the ECG recording (if < 30 seconds). (LOE C) Class I
Clinical definition/diagnosis Clinically significant POAF: Intra- and post-operative AF requiring treatment, or anticoagulation, and/or extending the duration of hospitalization. (LOE C) Class I
These measures should be included in the clinical documentation and reported in the clinical trials/studies.
Abbreviations: CoR: Class of recommendation; LOE: Level of evidence
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Table 5
Recommendations for Physiologic (ECG) Monitoring
Recommendations for Monitoring COR
Patients should be monitored with continuous ECG telemetry postoperatively for 
48–72 hours (or less if their hospitalization is shorter) if:
Class I
• they are undergoing procedures that pose high (> 15% expected incidence of AF) or 
intermediate (5–15%) risk for POAF or
• they have significant additional risk factors (CHA2DS2-VASc >2) for stroke (LOE 
C).
• they have a history of preexisting or periodic recurrent AF before their surgery.
These patients should also receive ECG monitoring in the immediate preoperative period if 
procedures (epidural catheter, regional anesthesia blocks, etc.) are performed. (LOE C).
Not using routine ECG telemetry is reasonable for patients who
○ undergo low risk surgery (<5% expected incidence of AF) and
○ had no prior history of AF, or
○ have no significant risk for stroke and
○ have no relevant co-morbidities (like heart failure or prior stroke). (LOE C)
Class IIa
If patients exhibit clinical signs of possible AF while not monitored with ECG telemetry, ECG 
recordings to diagnose POAF and continuous telemetry to monitor the period of AF should be 
immediately implemented. (LOE C)
Class I
Abbreviations: COR: Class of Recommendation; LOE: Level of Evidence; CHA2DS2-VASc: CHA2DS2-VASc score
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Table 6
Commonly Used Rate Control Agents
Drug Recommended doses Significant limitations and known side effects









Accumulates in acute kidney injury/chronic kidney 
disease










Amiodarone 150–300 mg i.v. over 1 hour, followed by 10–50 mg/hour i.v. continuous infusion over 24 hours
Bradycardia
QT interval prolongation
Pulmonary toxicity has not been demonstrated at 
this dose
*
Detailed information in Section 3 of the online version of the guidelines and in Refs 1 and 2
Abbreviations: AV: atrio-ventricular; i.v.: intravenous;
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Table 7
Commonly Used Anti-Arrhythmic Agents
Drug Recommended doses Significant limitations and known side effects Ref.
Procainamide
Conversion to sinus rhythm: 20–50 mg/min i.v. 
continuous infusion until AF terminated, hypotension 
occurs, or QRS duration prolonged by 50%, or 
cumulative total dose of 17 mg/kg reached
Alternative dose: 100 mg i.v. every 5 minutes until AF 
terminated or other conditions as listed above are met




Contraindicated in patients with heart failure 
with reduced left ventricular ejection fraction
Contraindicated in patients with pretreatment 




Conversion to sinus rhythm: 200–300 mg single oral 
dose






Contraindicated in patients with heart failure 
with reduced left ventricular ejection fraction




Conversion to sinus rhythm: 450–600 mg single oral 
dose
Maintenance of sinus rhythm: 150–300 mg orally every 
8 hours (immediate release); 225–425 mg orally every 





Contraindicated in patients with heart failure 
with reduced left ventricular ejection fraction




Prophylaxis: 300 mg i.v. bolus, then 600 mg orally 
twice daily for 5 days
Treatment: 150 mg i.v. over 10 minutes; then 1 mg/min 
i.v. continuous infusion for 6 hours; the 0.5 mg/min i.v. 









Pulmonary toxicity has occurred at cumulative 




Not indicated for conversion to sinus rhythm
Maintenance of sinus rhythm: Calculated creatinine 
clearance (CrCl) 20–40 mL/min: 125 mcg orally once 
every 12 hours
Calculated CrCl 40–60 mL/min: 250 mcg orally once 
every 12 hours;




Risk of torsades de pointes is greater in patients 
with heart failure
Dose adjustment is very important in patients 
with acute kidney injury or chronic kidney 
disease
Contraindicated in patients with calculated CrCl 
< 20 mL/min
Contraindicated in patients with pretreatment 
QTc interval > 470 ms (males) or 480 ms 
(females)




Conversion to sinus rhythm:
Weight ≥ 60 Kg: 1 mg i.v. administered over 10 
minutes
Weight < 60 Kg: 0.01 mg/Kg i.v. administered over 10 
minutes
If the AF does not terminate within 10 minutes of 
completion of the 1st infusion, a 2nd dose of equal 
strength may be administered i.v. over 10 minutes
Not indicated for maintenance of sinus rhythm
QT interval prolongation
Torsades de pointes
Risk of torsades de pointes greater in patients 
with heart failure
Nonsustained ventricular tachycardia
Sinus pauses following AF conversion
Contraindicated in patients with pretreatment 








Not indicated for conversion to sinus rhythm
Maintenance of sinus rhythm: 40–160 mg orally every 
12 hours
Dosing interval should be adjusted in patients with 
acute kidney injury or chronic kidney disease:
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Drug Recommended doses Significant limitations and known side effects Ref.
Calculated creatinine clearance 10–29 mL/min – every 
36–48 hours
Risk of torsades de pointes greater in patients 
with heart failure
Bronchospasm
Dose adjustment is very important in patients 
with acute kidney injury or chronic kidney 
disease
Use with extreme caution in patients with 
calculated CrCl < 10 mL/min and in patients 
undergoing hemodialysis
Contraindicated in patients with pretreatment 
QTc interval > 470 ms (males) or 480 ms 
(females)
Abbreviations: AV: atrio-ventricular; i.v.: intravenous; CrCl: creatinine clearance;
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